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ABSTRACT 
Nicole Fenton: The Adolescent Health Belief Model: Conceptualizing Cognitive Factors That 
Influence Medication Non-Adherence Among Adolescent 
(Under the direction of Don Baucom) 
 
The medication non-adherence literature rarely employs theoretical models, and no 
models to date have been modified or created to understand adolescent medication non-
adherence. The first aim of this study was to evaluate whether the six factors in the child health 
belief model (CHBM; susceptibility, severity, family support, benefits, barriers, self-efficacy) 
could be employed to understand adolescent medication non-adherence. The second aim was to 
propose a developmentally appropriate extension of the CHBM and provide an initial empirical 
evaluation of this model. This new more complete model is called the adolescent health belief 
model, and includes all factors of the CHBM as well as peer support and personal control. 
Participants were recruited from the UNC Chapel Hill Pediatric outpatient clinics and included 
110 adolescents age 13-21 with a diagnosis of inflammatory bowel disease or chronic kidney 
disease. Results indicated that the CHBM as a whole was a significant predictor of medication 
non-adherence. Additionally, the factors of perceived benefits, barriers, and self-efficacy were 
each significant individual predictors of non-adherence above and beyond the other predictors in 
the model. The AHBM as a whole remained a significant predictor of non-adherence. The added 
factors of peer support and personal control, however, were not significant. Overall, results 
indicate that there is empirical evidence for the use of the CHBM. Further, it may be that 
concrete, proximal, cognitive factors such as benefits, barriers, and self-efficacy are of critical 
importance when trying to understand an adolescent’s medication non-adherence.
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 CHAPTER 1: INTRODUCTION 
Chronic illnesses are pervasive, affecting approximately 10-20% of children in the United 
States (Davidoff, 2004; Judson, 2004). Two frequently understudied chronic illnesses among 
youth are Inflammatory Bowel Disease (IBD) and Chronic Kidney Disease (CKD). Whereas 
there are no cures for these chronic illnesses, scientific advances have resulted in an increased 
survival rate for children with even the most severe stages of these conditions. One key 
component to successful illness management and increased survival is adherence to medical 
treatment (Finea et al., 2009). Adherence is defined as taking medication in a way that 
corresponds with the recommendations from a healthcare provider (Sabate, 2003). When patients 
do not follow their medication regimen as prescribed or are non-adherent to their medications, 
many serious complications can occur, such as increased disease activity, frequent 
hospitalizations, and even death (Dew et al., 2001; Falkenstein, Flynn, Kirkpatrick, Casa-Melley, 
& Dunn, 2004). Non-adherence and the subsequent complications occur across all ages; 
however, non-adherence occurs most frequently among adolescents (Dobbels et al., 2005; 
Rianthavorn & Ettenger, 2005). Consequently, many national consensus reports and conference 
proceedings have highlighted the need to better understand factors leading to and preventing 
non-adherence in adolescence (Finea et al., 2009).  
Some authors have proposed that the best way to understand non-adherence is to have a 
conceptual model of the phenomenon (La Greca, 1990). Despite this call for a conceptual model, 
adolescents have been widely overlooked in the non-adherence literature, and no models to date 
have been modified or created to understand adolescent medication non-adherence. Thus, the 
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current investigation will seek to fill this gap in the literature by suggesting a developmentally 
appropriate model to conceptualize medication non-adherence among adolescents, along with an 
initial empirical evaluation of this model. 
Outline of this Paper and Aims of the Current Study 
This paper begins by providing a review of non-adherence and the negative consequences 
that can result from it. Next, as adolescents are most at risk for non-adherence and 
physiologically have the poorest outcomes due to non-adherence, a rational for focusing on 
adolescents is provided. Then, it will be suggested that since adolescents are primarily in charge 
of their medications, cognitive factors or ways in which adolescents think about medication 
adherence are key components to understanding adolescent non-adherence. One health model 
that focuses on cognitions and is frequently used in the pediatric literature is the Child Health 
Belief Model (CHBM). The CHBM has six components: perceived severity, susceptibility, 
benefits, barriers, self-efficacy, and family support. Whereas no investigators to date have 
examined the entire CHBM in adolescents, some studies have addressed specific components of 
the CHBM. The current investigation was the first to review the empirical support for using the 
CHBM in adolescents. This review demonstrates that while there are mixed findings regarding 
whether there is a positive or negative relationship between some of the factors and non-
adherence, there is clear evidence for the use of the CHBM in adolescents. Examining each 
factor independently does not allow for the examination of the relative contribution of each 
factor in predicting non-adherence. Thus the current study was the first to evaluate the full model 
and examine the relative contribution of each factor.  
Additionally, as the CHBM was developed for pre-adolescents, it does not take into 
account some of the developmental factors unique to adolescents. Thus, I propose that by adding 
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two factors to the CHBM (peer support and perceived control), the adolescent health belief 
model (AHBM) will explain significantly more variance in adolescent non-adherence than the 
CHBM alone. The AHBM will be evaluated in two different illness populations, chronic kidney 
disease (CKD) and inflammatory bowel disease (IBD). This section will finish by proposing a 
conceptual framework to understand how different components of the AHBM may be 
differentially important depending on the characteristics of the illness. 
Medication Non-Adherence 
The concept of “compliance” was first introduced by The World Health Organization and 
is defined as patients acting in accordance with their doctors’ recommendations (Haynes, Taylor, 
& Sackett, 1979). In recent years, the term ‘compliance’ was criticized as too simplistic because 
it implies a clear hierarchy between the patient and the physician and ignores the patient’s 
thoughts, feelings, and decisions in the process. The term has since been replaced with 
“adherence” (Feinstein, 1990), which is defined as, “The extent to which a person’s behavior 
corresponds with agreed recommendations from a healthcare provider” (Sabate, 2003, pp. 3–4). 
A patient’s treatment adherence can refer to a range of behaviors such as exercise, dietary 
modifications, appointment attendance, fluid intake, and taking medications. While all these 
different components can play a role in a patient’s treatment, approximately 65% percent of 
doctors state that medication adherence is the most important factor in the care of their patient’s 
illness (Ferris et al., 2011). Thus this investigation will focus on medication non-adherence. The 
exact rate of medication non-adherence among pediatric populations is not known; however, 
there is a consensus across studies that rates of non-adherence are above 50% (Dunbar-Jacob & 
Mortimer-Stephens, 2001; La Greca & Bearman, 2003; Rapoff, 1999). One limitation of all non-
adherence research is that participants are often involved in medical care, recruited from a 
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physician’s office, and include only those willing to participate. This may result in even the 
highest estimates of non-adherence being too low (LaGrecca, 1988). Despite these uncertainties, 
it is clear that across chronic illnesses, rates of pediatric non-adherence are consistently high 
(Bucks et al., 2009; Hommel & Baldassano, 2010).  
When pediatric patients do not follow their medication regimen as prescribed or are non-
adherent to their medications, many serious complications may occur, such as increased 
medication dosage, increased disease activity, drug resistance, drug reactions, higher health care 
costs, reduced health-related quality of life, frequent hospitalizations, and even death (Dew et al., 
2001; Falkenstein, Flynn, Kirkpatrick, Casa-Melley, & Dunn, 2004; Kelly & Kalichman, 2002; 
Rohan et al., 2010; Sudan, Shaw, & Langnas, 1997; Van Dyke et al., 2002).  For example 78 
adolescents with IBD were asked to self-report their medication adherence. Those with lower 
medication adherence had greater disease activity and lower health-related quality of life. In 
another study, it was found that among adolescents with CKD, non-adherence accounted for 
71% of cases of graft loss and disease progression (Jarzembowski et al., 2004). Overall, non-
adherence compromises the health outcomes of pediatric treatments by an average of 33%, and it 
may be as much as 71% (DiMatteo Giordani, Lepper, & Croghan, 2002). In addition to the 
negative implications for the patient, non-adherence also affects the health care system and the 
overall use of societal resources (Bronfenbrenner, 1979; Pai & Drotar, 2010). The increased 
patient demands caused by non-adherence reduce the amount of time healthcare providers have 
for other appointments or patients (Bender & Rand, 2004). Also across all ages, reported annual 
hospitalization costs due to medication non-adherence total from US$735 million in Ontario, 
Canada (Iskedjian, Addis, & Einarson, 1998) up to US$13.35 billion in the U.S. (Sullivan, 
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Kreling, & Hazlet, 1990). Overall, these findings suggest a clear cost of non-adherence in terms 
of monetary value and negative health implications.  
Whereas the negative outcomes of non-adherence have been well documented, the best 
way to operationalize and measure non-adherence is less clear. Across studies, there is not a 
common definition of non-adherence. Some authors conceptualize non-adherence as a 
continuous variable while other authors determine a critical ‘cut-point’ and operationalize 
adherence and non-adherence as a dichotomous variable. For example in the diabetes and asthma 
literature, if a patient misses approximately 15 or 20% of their medications, they are considered 
non-adherent (Dracup & Meleis, 1982). However in the HIV and transplant literature, a patient 
only needs to miss approximately 5 or 10% of their medications to be considered non-adherent 
(Osterberg & Blaschke, 2005). A number of problems may arise from using a dichotomous 
definition. For example, someone who misses 70% of their medications and someone who 
misses 30% of their medications would both be considered non-adherent; however, their pattern 
of medication taking is clearly quite different. Given this limitation, non-adherence may be most 
accurately understood as a continuous variable. Conceptualizing non-adherence along a 
continuum may allow more information about the person’s medication regimen to be conveyed.  
Even if an agreed upon definition of non-adherence is derived, there are a number of 
different ways that information about non-adherence can be collected, thus impacting estimates 
of non-adherence.  Assessments of non-adherence can include a person’s self-report, doctor’s 
report, parent’s repot, drug levels (the amount of medication in the person’s blood), digitized pill 
caps (a medication top that records each time it is opened), or pharmacy refill rate (contacting the 
pharmacy and obtaining information regarding the refill history). These different approaches 
attempt to capture the construct of non-adherence, but these varying methods typically have quite 
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different results (Nakonezny et al., 2010). Comparing objective measures (e.g., pill caps, blood 
levels, pharmacy refill rates) and subjective measures (e.g., self-report, doctor report, parent 
report)  of adherence, findings indicate that studies using subjective measures are more numerous 
and yield lower average non-adherence scores than studies using objective measures (Dimatteo, 
2004). This phenomenon has been observed in a number of studies, yet the exact mechanism 
accounting for these findings has not been examined. It has been proposed that high levels of 
social desirability may result in participants minimizing their self-reported non-adherence (Malee 
et al., 2009). A number of studies in other areas have shown that social desirability results in 
participants modifying their answer to reflect what they perceive as the more socially desirable 
response (Arnold & Feldman, 1981; Mortel, 2008). If this were the case, it would suggest that 
self-reported non-adherence is not as accurate as some of the alternate methods of gathering non-
adherence data. Alternatively self-reported data might be a valid assessment strategy and may be 
higher because people are, in fact, being less non-adherent than what other methods indicate. 
Overall, the mechanism accounting for lower self-reported non-adherence needs to be elucidated, 
and there is not a clear understanding of the best way to measure non-adherence. As a result of 
this uncertainty in measurement, many researchers use a multi-method approach and obtain a 
number of different measures of non-adherence. 
Despite these methodological shortcomings, the negative implications of non-adherence 
for a patient’s physical and mental health have been well established. One group at particular risk 
for negative health outcomes are adolescents. When compared with younger children or older 
adults, adolescents are at significantly greater risk for non-adherence (Dobbels et al., 2005; 
Rianthavorn & Ettenger, 2005) and at higher risk for disease progression due to this non-
adherence (Gordeuk et al., 2008; Seiffge-Krenke, 1998; Sweet et al., 2006).  
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Non-Adherence in Adolescence 
Adolescence typically is a time of uncertainty about the future with increased 
independence, decision making, peer criticism, and risk taking (Arnett, 1992; Duncan, 1993; 
Holmbeck & O’Donnell, 1991). For adolescents with a chronic illness, medication non-
adherence may be another domain of risk taking. Additionally, there are a number of 
pathophysiological changes that occur during adolescence, that subsequently increase the 
likelihood of negative health outcomes. For example, there is a steep decline in renal function as 
adolescents go through puberty and the early post pubertal period (Ardissino et al., 2003). The 
reason for this increased risk is unknown; however, it is speculated that it may be due to sex 
hormones or an imbalance between the kidney’s size and a rapidly growing body size (Warady 
& Chadha, 2007). This increased risk for disease progression also occurs in adolescents with 
diabetes, transplant recipients, and sickle cell disease (Gordeuk et al., 2008; Seiffge-Krenke, 
1998; Sweet et al., 2006).  At the time when physiologically it is most important to be adherent 
to their medications, adolescents might be the most likely to take risks and be non-adherent.  
In addition to the behavioral and physiological changes that occur during adolescence, 
adolescents are beginning to take more responsibility for their health and overall healthcare.  
Specifically, they are taking a more active role in their illness management, healthcare decision 
making, and self-advocacy (Institute of Medicine, 2007). In fact, the majority of adolescents 
report that they are the primary person in charge of their medications (e.g., remembering to take 
them, calling in refills; Shemesh et al., 2004). Because the adolescent is the main person 
deciding whether to take her/his medication, their cognitions about the positive and negative 
implications of the medication may play a key role in influencing non-adherence. Studies have 
examined whether objective facts or subjective thoughts and beliefs play more of a role in an 
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adolescent’s non-adherence, and the findings suggest that the subjective thoughts may be more 
significant. For example, in a sample of 45 adolescents with IBD, a patient’s objective disease 
severity (as measured by examining their medical record) was not predictive of their medication 
non-adherence, whereas the adolescent’s perceived disease severity was a significant predictor 
(Reed-Knight et al., 2010). Other studies have found that some objective barriers are not 
predictive of non-adherence, whereas perceived barriers to medication taking (e.g., not wanting 
to be seen as different) have been found to be significant predictors of non-adherence (Rudy, 
Murphy, Harris, Muenz, & Ellen, 2010; Zelikovsky, Schast, Palmer, & Meyers, 2008). These 
studies suggest that the adolescent’s thoughts and beliefs may predict non-adherence more 
accurately than objective factors.   
 To better understand the role of thoughts and beliefs in medication non-adherence, it is 
helpful to have an overall framework and conceptualization of the behavior (La Greca, 1990). A 
model has been defined as, “A set of general or abstract principles based on experimentally 
established relationships among events to explain a phenomenon” (Johnston & Pennypacker, 
1993, pp. 371). While the idea of incorporating models for non-adherence has been proposed in 
the literature, few authors in the pediatric field have applied models when designing or 
conceptualizing studies examining non-adherence. However, the adult literature has several 
theories that have been proposed to conceptualize how psychosocial factors, cognitive factors, 
and environment factors influence non-adherence.  
The Child Health Belief Model 
The more highly regarded models used to understand adult health behaviors include: the 
Social-Cognitive Theory (Bandura, 1986), Theory of Reasoned Action and Planned Behavior 
(Montaño, Kasprzyk, & Taplin, 1997), Transtheoretical Model (Prochaska, 1979), the Applied 
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Behavior Analytic Model (Rapoff, 1996; Zifferblatt, 1975), and the Health Belief Model (Janz & 
Becker, 1984; Rosenstock, 1974). Each of these models has important strengths, but over the 
past five decades, the Health Belief Model (HBM) has emerged as one of the most empirically 
supported and frequently used models in the health behavior literature (Clark & Houle, 2009; 
Strecher & Rosenstock, 1997).  
It is important to review the history of the HBM to highlight how the changes and 
modifications made over time have led to the current version. The original HBM had five main 
components (perceived susceptibility, perceived severity, perceived benefits, perceived barriers, 
and cues to action), and it was later modified to include self-efficacy (Strecher & Rosenstock, 
1997). The model was originally developed to understand why adults failed to take advantage of 
preventive health services, such as immunizations and screenings for hypertension or breast 
cancer (Fink, Shapiro, & Lewison, 1968; Haefner & Kirscht, 1970; Johnson, 1962). The HBM 
was later extended to conceptualize non-adherence within adult populations (Barclay et al., 
2007). Once the HBM was extended to understand why adults may not follow their prescribed 
medication regimen, it was also used to understand children’s medication non-adherence 
(Gochman, 1981). The HBM has been adapted for use specifically in pre-adolescent populations, 
and it is called the Child Health Belief Model (CHBM; Bush & Iannotti, 1990). This model 
includes the same dimensions as the HBM (except cues to action), and it also incorporates the 
child’s perceived familial support. The factors in the CHBM are not drastically different from the 
HBM; however, the CHBM provides a developmentally appropriate way to conceptualize the 
factors influencing children’s health behaviors. Thus, the creation of the CHBM was an 
innovative and significant contribution.  
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The HBM and the CHBM are two ways to understand how adults and children with a 
chronic illness think and feel about their medications and how these thoughts and feelings 
influence their decision to be non-adherent. While adolescence is the developmental period when 
non-adherence is most likely to occur (Dobbels, Van Damme-Lombaert, Vanhaecke, & Geest, 
2005; Rianthavorn & Ettenger, 2005), no models to date have been created or modified for 
adolescents. Without a developmentally appropriate model to conceptualize adolescent non-
adherence, the majority of studies conducted to date have not used any model. Given that many 
adolescents report that they are primarily in charge of their medications and that cognitive factors 
are especially important in adolescents (Reyna & Farley, 2006), it may be that the CHBM should 
be expanded for use in adolescents. A few studies have used components of the CHBM when 
examining adolescent non-adherence; however, no studies to date have examined all factors of 
the CHBM at once. Nor has anyone assessed whether there is strong empirical support for the 
use of the CHBM in adolescents when all conducted studies are examined. The studies 
conducted to date that have assessed one or two factors of the CHBM give important information 
regarding the current empirical support for the CHBM in adolescents.  
The next six sections will review investigations that examine CHBM factors and non-
adherence in adolescents. The findings demonstrate that while there are mixed results regarding 
whether there is a positive or negative relationship between some of the factors and non-
adherence, there is clear support for the use of the CHBM in adolescents. Next, two additional 
factors (peer support and perceived control) will be proposed as developmentally appropriate 
additions to the CHBM. This new more complete model will be referred to as the Adolescent 
Health Belief Model.   
10 
 
Perceived susceptibility is one’s subjective perception of personal susceptibility to a 
negative health outcome if non-adherent (Bush & Iannotti, 1990; Janz & Becker, 1984; 
Rosenstock, 1974). Multiple studies have shown that most people, under most conditions, view 
their own chances of misfortune as lower than those of other people (Weinstein, 1998). This 
phenomenon occurs across all ages; however, in adolescence this low perceived susceptibility is 
most likely to translate into higher rates of risk taking (Kisker, 1985; Tauer, 1983).  
Three studies to date have examined the relationship between perceived susceptibility 
and non-adherence. The results have consistently found a significant relationship; however, there 
is a different pattern of findings across the studies. The results from two of the studies indicate 
that when adolescents perceived more susceptibility, they were less likely to be non-adherent 
(Brownlee-Duffeck et al., 1987; Foster et al., 2011). However in the third study, higher perceived 
susceptibility was positively related to both objective and subjective non-adherence (Bond, 
Aiken, & Somerville, 1992). These mixed findings suggest that while a relationship exists 
between perceived susceptibility and non-adherence, at the present time, the specific direction of 
the relationship is uncertain.  
To better understand the influence that perceived susceptibility has on non-adherence, it 
is important to examine why these mixed findings may occur. Therefore, two alternate 
explanations will be examined: measurement issues and moderators. A measurement issue may 
account for these discrepant findings. The three previous studies used different scales, two of 
which were developed for the individual study. Thus, it may be that the discrepant findings are 
due to the fact that while all three of the scales were attempting to capture the construct of 
perceived susceptibility, they were not, in fact, doing so or did so in substantially different ways.  
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A second explanation for these discrepant findings may be that there is a moderator 
occurring (i.e., coping style). This suggests that although they might have equally high levels of 
perceived susceptibility, some adolescents engage in one type of coping while other adolescents 
engage in another type of coping. These different types of coping strategies then result in 
different levels of non-adherence. For example, it may be that when some adolescents experience 
high perceived susceptibility, they engage in positive problem solving and are more likely to take 
their medications (Tercyak, Goldman, Smith, & Audrain, 2002). Other adolescents however, 
may experience high perceived susceptibility and use the coping strategy of denial, which in turn 
would make them less likely to take their medications. Studies have shown that when 
adolescents react with denial, they have poorer disease management and more medication non-
adherence (Jaser & White, 2011). Investigations also have demonstrated that when adolescents 
engage in positive problem solving, they have better disease management (Hill-Briggs, 2003) 
and less medication non-adherence (Thomas, Peterson, & Goldstein, 1997). The role of coping 
strategies in the relationship between perceived susceptibility and medication non-adherence has 
not been examined to date, thus providing an important focus for future investigations.  
The second cognitive variable included in the CHBM is perceived disease severity, which 
refers to one’s feelings concerning the seriousness of medical or clinical consequences if a 
person is non-adherent (Bush & Iannotti, 1990; Janz & Becker, 1984; Rosenstock, 1974). 
Perceived susceptibility examines how likely it is that a negative health outcome will happen to 
you; perceived disease severity addresses how adverse the negative outcome will be, given that a 
negative health outcome may occur (if you do not treat your illness), The domain of perceived 
susceptibility asks an adolescent to examine the odds of a negative outcome occurring, whereas 
perceived disease severity asks the adolescent to assess the magnitude of a negative outcome.  
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Few investigators have examined perceived disease severity in adolescent populations. 
The existing studies consistently suggest that perceived disease severity is a significant predictor 
of medication non-adherence; however, the pattern of findings differs among investigations. One 
study reported that self-reported perceived disease severity was significantly negatively 
associated with non-adherence (Brownlee-Duffeck et al., 1987). However, two other 
investigations found that higher perceived disease severity was predictive of higher medication 
non-adherence (Bond et al., 1992; Reed-Knight et al., 2010). These discrepant findings may be 
occurring because of measurement issues or a moderator as described above (e.g., coping style). 
A potential next step may be for researchers to ensure the use of previously used scales and 
examine the role that coping styles may be playing in this relationship.  
The third variable in the CHBM is perceived benefits, which refers to the adolescent’s 
perception that the recommended health action (i.e., the prescribed medication) is efficacious 
(Bush & Iannotti, 1990; Janz & Becker, 1984; Rosenstock, 1974). For example, a question 
focused on examining perceived benefits may ask, “How much do you think your medications 
can help your illness?” A study on risk taking found that among adolescents, perceived benefits 
are better determinants of behavior change for risk taking behaviors than are perceived risks 
(Parsons, Siegel, & Cousins, 1997). Despite this finding, only two studies to date have examined 
perceived benefits in adolescents, which make it the least researched component of the CHBM. 
Results indicated that when adolescents had higher perceived benefits, they were significantly 
less non-adherent (Bucks et al., 2009; Zugelj et al., 2010). These two studies suggest that 
perceived benefits play a role in medication non-adherence; however, given that few studies have 
examined perceived benefits, these results should be interpreted with caution. 
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  The fourth and final component of the original CHBM is perceived barriers. This refers 
to the perceived costs or negative consequences of taking medications (e.g., expense, side 
effects, perceptions of being different, taste of the medication; Bush & Iannotti, 1990; Janz & 
Becker, 1984; Rosenstock, 1974). Perceived barriers and structural barriers are two different 
types of barriers that researchers have examined. Structural barriers refer to factors in everyday 
life that can result in non-adherence. These factors may include medical insurance, the cost of 
the medications, transportation to get medications, and difficulties getting the medications filled 
(Rudy, Murphy, Harris, Muenz, & Ellen, 2010). Patients frequently self-identify structural 
barriers as a factor contributing to their non-adherence (Evans et al., 2010); however, even when 
studies have accounted for structural barriers, non-adherence still occurs (Gincherman, Moloney, 
& Mckee, 2010). This suggests that while structural barriers may be contributing to non-
adherence, perceived barriers are also playing a role. 
 The most studied domain in the original child health belief model is perceived barriers. 
Thus far, nine studies have examined the relationship between perceived barriers and non-
adherence. These studies have been conducted across a range of chronic illness populations 
(inflammatory bowel disease, transplantation, type 1 diabetes, human immunodeficiency virus, 
transplant candidates, and asthma), and all the studies have found that when adolescents have 
higher levels of perceived barriers, they are more non-adherent to their medications (Hommel & 
Baldassano, 2010; Ingerski, Baldassano, Denson, & Hommel, 2010; Ratcliff, Blount, & Mee, 
2010; Simons, McCormick, Devine, & Blount, 2010; Simons, McCormick, Mee, & Blount, 
2009; Zelikovsky, Schast, Palmer, & Meyers, 2008).  
14 
 
The Four Original Components of the Child Health Belief Model 
The studies discussed thus far suggest that an adolescent’s thoughts play an important 
role in medication non-adherence. When adolescents perceive their medications as beneficial and 
identify few barriers to taking their medications, they are less non-adherent. Whereas there is a 
different pattern of findings across studies for perceived susceptibility and perceived severity, it 
is clear that the thoughts adolescents have about their susceptibility to negative health outcomes 
and the severity of those negative health outcomes play a role in medication non-adherence. 
These findings provide important information when trying to understand why one adolescent is 
adherent and another is not. Additionally, these findings suggest that there is clear empirical 
evidence for the use of the four original components of the CHBM when examining medication 
non-adherence in adolescents. 
Family support was the final component added to the CHBM. This factor differs from the 
prior factors in that it does not focus on individuals’ thoughts and feelings about the medication, 
the possible negative consequences if they do not take their medications, or their perceived 
ability to implement the medication regimen. Rather, this domain focuses on the adolescent’s 
perception of other people’s thoughts and behaviors, specifically, the family’s support in 
facilitating medication taking (Bush & Iannotti, 1990).  For example, when assessing family 
support in this context, a clinician may be interested in understanding how family members 
emphasize or minimize the importance of the adolescent taking their medications. This domain 
was added to the CHBM as children are rarely fully in charge of taking their own medications; 
they may not be able to drive to the store to get the medications, and they may not be old enough 
to comprehend the purpose of the medications. Among children and adolescents with a chronic 
illness, family functioning more broadly has been shown consistently to negatively predict 
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medication non-adherence (Grey, Boland, Sullivan-Bolyai, & Tamborlane, 1998; Hsin, La 
Greca, Valenzuela, Moine, & Delamater, 2010; La Grecca & Auslander, 1995). Few authors 
however, have specifically examined the family’s support for medication taking. Four studies 
have examined this specific type of family support and found that with adolescents, higher 
family support for medication significantly negatively predicts medication non-adherence (Hsin, 
La Greca, Valenzuela, Moine, & Delamater,  2010; Lewin et al., 2006; Reed-Knight, Lewis, & 
Blount, 2010; Tucker et al., 2002). These findings suggest that family support more broadly, as 
well as familial support for medication taking specifically, are both important predictors of an 
adolescent’s non-adherence.  
The second version of the HBM was modified to include self-efficacy. Bandura defines 
self-efficacy as the belief that one can carry out specific behaviors in specific situations (1997). 
There are two different ways in which self-efficacy can influence the likelihood that one will 
engage in a behavior. First, someone will be less likely to engage in a behavior (i.e., taking their 
medications) if they see themselves as less able to perform the behavior (i.e., think they will not 
take them correctly). Second, if an individual's self-efficacy for the behavior is low, and they 
encounter an obstacle, the probability that the individual will successfully perform the behavior 
is decreased. Specifically, this individual will tend to exert less effort for a shorter period of time 
than an individual with higher perceived self-efficacy for the behavior (Bandura, 1977). For 
example, if an adolescent is scheduled to go to the nurse’s office to take their medications and 
they forget, a person with low self-efficacy might spend less time and effort trying to come up 
with an alternate plan to take them later in the day. Overall, studies have found that self-efficacy 
is an important factor in influencing short-term and long-term health behavior changes in both 
children and young adults (Holden, Moncher, Schinke, & Barker, 1990; Holden, 1991). Four 
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studies to date have examined the relationship between self-efficacy and non-adherence. The 
findings across the four existing studies have indicated consistently that when adolescents have 
higher levels of self-efficacy, they have lower levels of medication non-adherence (Berg et al., 
2011; Rudy, Murphy, Harris, Muenz, & Ellen, 2010; Stewart et al., 2003; Tucker et al., 2002). 
 Bandura proposed that not only is self-efficacy or the belief that one can carry out 
specific behaviors important in influencing a person’s behavior, but  a person’s perception of 
their personal control also needs to be considered.  
Adolescent Health Belief Model   
Looking across the six components of the CHBM, there is compelling empirical support 
for the use of this model in adolescents. Specifically, cognitions about perceived severity, 
perceived susceptibility, perceived benefits, perceived barriers, self-efficacy, and familial 
support, are each playing a role in the adolescent medication-taking process. Although there is 
strong empirical evidence for each of these components, using a model that was designed for 
pre-adolescents in adolescents may ignore two developmentally unique factors. Thus, it is 
proposed that the addition of two new factors, perceived control and peer support, should be 
added to the CHBM and that this more complete model, AHBM, will more fully explain the 
phenomenon of adolescent non-adherence.  
Personal control is the extent to which someone feels that their behaviors can influence 
and change a given outcome. Someone with high personal control would operate with the view 
that a given outcome can be modified based on their actions; however, someone with low 
personal control would think that regardless of what they do, a given outcome cannot be 
influenced (Bandura, 1993). For example, a person with high personal control for their illness 
may think that by taking their medications they can influence the course of their disease 
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progression or control the symptoms of their illness. Someone with low personal control for their 
illness may think that taking their medications will not influence the course of their disease 
progression or change their symptoms.  
The concept of personal control, sometimes also referred to as outcome expectations, is 
similar yet distinct from self-efficacy. Self-efficacy is the belief that one can carry out a specific 
behavior whereas personal control refers to a person’s thoughts about the influence of engaging 
in that specific behavior. Thus, a person could have high or low self-efficacy and high or low 
personal control. Knowing about a person’s self-efficacy does not provide information about a 
person’s personal control. Studies have found that when predicting health behaviors, knowing 
both a person’s self-efficacy and a person’s personal control predicts significantly more variance 
than knowing either of these factors alone (Bandura, 1997). Despite these findings, only one 
study to date has examined the role of personal control in medication non-adherence. The 
findings indicated that when an adolescent has higher personal control, they were less non-
adherent to their diabetes regimen (Iannotti et al., 2006). Across studies, the results suggest that 
an adolescent’s perceived control and self-efficacy are both important factors to understand when 
attempting to gain a complete picture of the cognitive factors influencing non-adherence. 
As youth move from late childhood to early adolescence, their main source of social 
support changes. Specifically, peer relationships begin to gain increasing significance (Kerns, 
Contreras, & Neal-Barnett, 2000). Additionally, during this developmental period, the amount of 
time spent with friends increases, and there is a dramatic drop in the amount of time adolescents 
spend with their parents (Larson & Richards, 1991). The important role that peer social support 
can provide has been demonstrated across a range of domains. For example among adolescents, 
peer social support has been shown to play a significant role in overall adjustment, well-being, 
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emotional adjustment, self-esteem, and physical adjustment (Buchanan & Bowen, 2008; Matlin, 
Molock, & Tebes, 2011; Weiss et al., 2002). Conceptualizing the medication taking process for 
adolescents within a broader developmental framework, it may be that peers also play an 
important role in influencing medication non-adherence.  
The time spent with peers can influence an adolescent in both positive and negative ways. 
Peers can positively influence academic achievement and prosocial behaviors (Mounts & 
Steinberg, 1995; Wentzel & Caldwell, 1997); however, peers also can promote maladaptive 
behavior such as drug and alcohol use, cigarette smoking, and delinquency (La Greca, Prinstein, 
& Fetter, 2001; Urberg et al., 1997). The majority of research examining the role that peers play 
during adolescence has focused on health-risk behaviors (La Greca, 1990; Spirito, DeLawyer, & 
Stark, 1991). This may be a result of the tendency to view peers as obstacles to, rather than 
facilitators of, good health practices (e.g., Chassin, Presson, Sherman, Montello, & McGrew, 
1986; Gross, Johnson, Wildman, & Mullet, 1981). Thus, there is a need to further examine the 
potentially positive influence that friends may have in adolescent’s disease management and 
adaptive health behaviors such as low non-adherence.  
Two studies to date have examined the association between adolescents’ peer 
relationships and health-promoting behaviors. One such study was conducted with 74 
adolescents with diabetes. Participants completed the diabetes social support questionnaire for 
friends, and results indicated that peer support was predictive of higher levels of exercise and 
more frequent blood glucose testing (Bearman & La Greca, 2002).  In another study, 38 
adolescents with Irritable Bowel Disease completed the Social Experience Questionnaire (Crick 
& Grotpeter, 1996) and self-reported their medication non-adherence. When adolescents 
perceived higher levels of prosocial peer support, they were less non-adherent to their 
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medications (Janicke et al., 2009). While these are the only two studies conducted in adolescents, 
studies in both younger children and adults have each found a significant association between 
peer support and medication non-adherence (e.g., Heisler, Vijan, Makki,  & Piette, 2010; Levers-
Landis et al., 2002). Given these findings and the developmental stage of adolescence, peer 
social support is an additional factor that should be included when examining adolescent non-
adherence.  
 Overall, the health belief model has not been examined in a manner that takes all of the 
proposed factors into account simultaneously in predicting important outcomes such as 
medication non-adherence. The current investigation examined all components of the CHBM 
and the expanded AHBM. Another aspect of this model that has been neglected, involves 
examining how the model may operate differently in different disease populations. To date no 
investigators have proposed ways in which the components of the model may be differentially 
important based on disease symptomology.  
Evaluating the Adolescent Health Belief Model in CKD and IBD 
 One key factor that may influence an adolescents’ thought processes about their 
medications is the short term and long term consequences associated with medication non-
adherence, i.e., symptoms. It may be that for illnesses where patients experience immediate, 
aversive symptoms if they are non-adherent, different factors are important compared to illnesses 
in which these immediate symptoms do not occur. For example if a patient with IBD is non-
adherent to their medications, there is an immediate physiological repercussion-- they likely end 
up in the restroom. Conversely if a patient with CKD does not take their medications, there are 
no immediate aversive consequences; rather, it is in the long term that they experience disease 
progression and increased symptomology. To better understand how these short and long term 
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consequences may play a role in the AHBM, it is important to first review the characteristics, 
symptoms, and treatment for both IBD and CKD. 
According to the National Kidney Foundation, CKD is defined as having one of the 
following two characteristics: (a) having kidney damage for greater than or equal to three months 
due to structural or functional abnormalities, or (b) having a Glomular Filtration Rate (GFR) less 
than 60 ml/min/1.73 m^2 lasting for 3 months with or without kidney damage (Eknoyan & 
Levin, 2002). The GFR is an indication of the kidney’s ability to filter blood. The typical causes 
of CKD are congenital or genetic in younger children and acquired in adolescents and young 
adults (U.S. Renal Data System, Annual data report, 2001). Due to the varying underlying causes 
of CKD, it occurs across a spectrum from mild to severe (Ferris et al., 2008). The exact cause of 
CKD is currently unknown; however, a strong genetic predisposition is suggested by the 
clustering of CKD found in families (Bergman, Key, Kirk, Warnock, & Rostant, 1996). This 
genetic predisposition is disproportionately likely to affect ethnic minorities, more specifically 
African Americans (U.S. Renal Data System, Annual data report, 2001). Another group of 
individuals at increased risk for a steep decline in renal function are adolescents going through 
puberty and those in the early post pubertal period (Ardissino et al., 2003).  
The onset of CKD can be difficult to detect in both adults and children. This is due to the 
often asymptomatic nature of the disease in its early stages, or because it may masquerade as 
other common childhood ailments (Ferris et al., 2008). Once detected, there is a complex daily 
regimen required to manage the illness. This regimen consists of medications once, twice, or 
even three times a day, food and liquid restrictions, and frequent visits to the doctor (Ferris et al., 
2008). These patients often have a shorter stature and delayed puberty. One of the most common 
medications used to treat CKD is an oral steroid. Steroids can result in facial swelling, increased 
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acne, hair growth, and emotional lability. Thus, often patients may feel worse after taking their 
medications, and they do not experience any immediate positive effect. Another illness in which 
oral steroids are the typical medication used to treat the disease is IBD. However, in this illness, 
there are immediate consequences for taking or not taking medications.  
IBD has a relapsing and remitting course, with the most common symptoms in children 
including frequent diarrhea, abdominal pain, and weight loss or growth delay. Associated 
symptoms can include fever, fatigue, decreased appetite, arthritis, perianal disease, and delayed 
puberty. IBD is generally divided into two subtypes, Crohn’s disease and ulcerative colitis, 
which differ primarily in the anatomical location, nature of the inflammation, and possibly the 
underlying causative mechanisms. Crohn’s disease may occur anywhere in the intestinal tract, 
but ulcerative colitis is found only in the colon (large intestine). In ulcerative colitis, the 
intestinal inflammation is confined to the innermost layer of the intestinal wall, while the 
inflammation of Crohn’s disease can extend through the entire thickness of the intestinal wall. 
The specific etiologies are unknown, although both genetic and microbial factors are known to 
be involved (Rice & Chuang, 1999). An interaction between a dysregulated intestinal immune 
system and intestinal bacteria is thought to lead to the uncontrolled inflammation seen in IBD, 
although different immunological pathways are involved in Crohn’s disease and ulcerative 
colitis.  
The treatment of IBD has many characteristics similar to the treatment of CKD. There is 
a comparable and complex daily regimen required to manage the illness. This regimen consists 
of frequent medications, food restrictions, and frequent visits to the doctor. These patients also 
often have a shorter stature and delayed puberty. Additionally, the most common medication 
used to treat IBD is oral steroids. However, unlike patients with CKD, those with IBD have an 
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immediate positive effect after taking their medications-- it helps control their GI track and 
subsequent bowel movements. Thus, often patients feel better after taking their medications.  
The immediate physiological cue that adolescents with IBD experience when they are 
non-adherent to their medications may be a significant factor in determining an adolescent’s non-
adherence. Both perceived benefits and perceived severity are two components of the AHBM 
that focus on immediate short-term beliefs. As previously mentioned, when an adolescent with 
IBD takes their medication, they experience an immediate positive effect -- it helps control their 
GI track and subsequent bowel movements. This is not the case for adolescents with CKD. For 
those with CKD, the medication helps control the long term progression of the illness but does 
not have any short term, immediate benefits. Therefore the perceived short-term benefits of 
taking their medications may be a significant factor in predicting medication non-adherence for 
adolescents with IBD, but it may not be for those with CKD. In addition to the short-term 
benefits that adolescents experience when they take their medications, they also experience 
multiple relatively severe negative consequences if they do not take their mediations. 
Specifically, if adolescents with IBD do not take their medications, they may have uncontrollable 
bowel movements. This differs from CKD in that there are no immediate negative side effects if 
adolescents do not take their medications. In fact CKD is largely asymptomatic in its early 
stages. This suggests that in adolescents with IBD, the perceived severity of these negative 
consequences would be a significant predictor of non-adherence and that for those with CKD, 
this would not be the case. 
 Personal control is the extent to which someone feels that their behaviors can influence 
and change a given outcome. It may be possible that if participants with CKD think that taking 
the medication will in the long term decrease their disease progression, they will have lower 
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levels of non-adherence. Conversely, if they think that taking the medication will not influence 
their long term disease progression, they will have higher levels of non-adherence.  For patients 
with IBD, their perceived long term personal control may not be important; there are such potent, 
short term benefits and consequences associated with taking or not taking their medications that 
long term personal control may not be playing a role.  
Current Study Aims and Hypotheses 
 As was previously discussed, the AHBM may operate differently for the two illness 
populations. The subsequent hypotheses took this into account when appropriate. The first two 
hypotheses controlled for disease type. These two hypotheses focused on the definition of non-
adherence and the model as a whole; therefore, the differential role of the factors across the two 
diseases was not of primary interest. The third hypothesis examined whether the coping style of 
positive problem solving and denial moderate the relationship between susceptibility, severity, 
and non-adherence. This relationship was thought to hold true in both illness groups; therefore, 
the illness type was not controlled for. The final hypothesis examined how the various factors in 
the AHBM might be differentially important in the two illness populations. Thus, this hypothesis 
examined the possible moderating role that illness type could play in the relationship between the 
AHBM factors and non-adherence. 
Hypothesis 1. As previously discussed, there is not a gold standard method for 
measuring non-adherence. This study, therefore, employed four different methods to obtain non-
adherence information: self-report, doctor report, caregiver report, and pharmacy refill 
information (used to calculate the medication possession ratio; MPR). Given these four different 
measures of non-adherence, the aim of the first hypothesis was to characterize the relationships 
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among the four different measures of non-adherence and determine which measure(s) of 
medication non-adherence should be used in the subsequent hypotheses.  
While many previous investigators ran their hypotheses employing each different 
measure of non-adherence, this is problematic for two reasons. First, it increases the likelihood 
of type I error. Additionally, if each measure of non-adherence is conceptualized as a measure of 
the same underlying latent variable, then the data should be examined to determine if this is in 
fact the case. In order to characterize the relationships among the four different measures of non-
adherence and determine appropriate non-adherence measures for further analyses, three aims 
were put forth.  
The first aim was to examine the average non-adherence obtained by the four different 
measures of non-adherence. This allowed for a descriptive understanding of the four non-
adherence measures. Objective measures of adherence (MPR) typically indicate higher average 
levels of non-adherence than subjective measures of non-adherence (self-report, caregiver report, 
and doctor report). Hypothesis 1A proposed that non-adherence obtained by the MPR would be 
the highest, followed by the average non-adherence by doctor report, caregiver report, and that 
non-adherence by self-report would be the lowest. The four measures of non-adherence 
employed the same scaling approach, and each measure examined what percent of time the 
participant did not take their medications. Therefore the four measures could be directly 
compared with each other. It was hypothesized that self-reported non-adherence would he lowest 
as it has been suggested that social desirability significantly influences self-report such that 
individuals want to appear compliant in their ratings (Malee et al., 2009).  
Hypothesis 1B stated that social desirability would be a significant negative predictor of 
self-reported, caregiver reported, and doctor reported medication non-adherence. It was 
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hypothesized that social desirability would not be a significant predictor of the MPR calculated 
non-adherence. If social desirability is found to be a significant predictor of non-adherence, then 
subsequent hypotheses will control for social desirability. 
The third aim was to determine if all four measures of non-adherence represent the same 
underlying latent variable (using confirmatory factor analysis; CFA) and determine what 
measures of non-adherence to use in the subsequent analyses. While a different pattern of 
findings were expected such that self-reported non-adherence would be lower than caregiver 
reported, doctor reported, or pharmacy obtained non-adherence (hypothesis 1A), it was 
anticipated that all four measures would be at least moderately correlated. Hypothesis 1C stated 
that there would be significant medium correlations among the four different measures and that a 
CFA model would have good fit indices (Figure 1).  
Based on the findings of hypothesis 1C, non-adherence will be operationalized in one of 
the following three ways. The first way would be if the CFA model had good fit indices and 
social desirability was not a significant predictor of any of the 4 non-adherence measures. In this 
case, the CFA would be used to combine the four measures of non-adherence into one overall 
variable (factor score). This is discussed at greater length in the data analysis section. The second 
possibility would be if the CFA model had good fit indices and social desirability was a 
significant predictor of any of the 3 non-adherence measures. In this case, all subsequent 
hypotheses would control for social desirability. The third outcome would be if the four 
measures of non-adherence did not have good fit indices, and, therefore, CFA is not an 
appropriate data analytic strategy. If this occurred, each subsequent hypothesis would be run 
with each individual non-adherence measure. For each of the four measures of non-adherence, if 
social desirability was a significant predictor of that particular non-adherence measure, it would 
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also be included in the model. Particular attention would be paid to the analyses run with the 
MPR since this is the most objective measure of non-adherence. This is discussed at greater 
length in the data analysis section. 
Hypothesis 2. In hypothesis 2A and 2B, first the total variance explained in medication 
non-adherence for the model was examined. Next, each factor in the model was examined to 
determine which factors were significant predictors of non-adherence. Within the Child Health 
Belief Model, Hypothesis 2A stated that that perceived susceptibility, perceived severity, higher 
perceived benefits, lower perceived barriers, higher family support, and higher self-efficacy 
would predict lower levels of medication non-adherence when disease type is controlled for. 
Hypothesis 2B examined whether the two new factors added to form the Adolescent Heath 
Belief Model were significant predictors of non-adherence. Specifically, Hypothesis 2B stated 
that personal control and peer support would be significant negative predictors of non-adherence 
when they were added to the model listed in Hypothesis 2A. Finally, the Adolescent Health 
Belief Model was developed as a developmentally appropriate and more complete way to 
conceptualize adolescent non-adherence. Hypothesis 2C stated that the Adolescent Health Belief 
Model (hypothesis 2B) would explain significantly more variance in medication non-adherence 
than the Child Health Belief Model (hypothesis 2A). 
            Hypothesis 3. Hypothesis 3 examined a possible explanation for the different pattern of 
findings shown across the factors of perceived susceptibility and perceived severity. Some prior 
studies found a positive relationship between susceptibility, severity, and non-adherence, 
whereas other studies found a negative relationship between susceptibility, severity, and non-
adherence. Thus, this hypothesis examined whether the coping styles of positive problem solving 
and denial moderate the relationships among susceptibility, severity, and non-adherence. 
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Hypothesis 3 stated that when participants experience perceived susceptibility or severity and 
engage in denial, they will have high non-adherence. However, when participants experience 
perceived susceptibility or severity but engage in positive problem solving, they will have low 
medication non-adherence. 
Hypothesis 4. Across the two chronic illnesses being examined in this investigation, there 
are multiple differences in both the short-term and long-term consequences of non-adherence. 
This secondary hypothesis examined if some of the AHBM factors are differentially important 
across the two illness groups. Because individuals with IBD experience strong negative, 
immediate consequences when non-adherent, the perceived severity of these short-term 
consequences and the perceived benefits of the medication may be particularity important 
factors. Hypothesis 4A stated that the relationship between the perceived severity of the short-
term consequences and non-adherence would be moderated by disease type. For participants 
with IBD, there would be a strong relationship between perceived severity of the short-term 
consequences and non-adherence; however, this would not be the case for those with CKD. 
Additionally, Hypothesis 4B stated that the relationship between perceived benefits and non-
adherence would be moderated by disease type. More specifically for participants with IBD, 
there would be a strong relationship between perceived benefits and non-adherence; however, 
this will not be the case for those with CKD. 
Hypothesis 4C stated that the relationship between personal control and non-adherence 
would be moderated by disease type. For participants with CKD, the long-term consequences of 
personal control would be more important when predicting medication non-adherence compared 
to individuals with IBD. 
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CHAPTER 2: METHOD 
Participants 
 Recruitment occurred at the UNC Chapel Hill Pediatric outpatient and inpatient Kidney 
Clinic and Gastroenterological (GI) Services. All patients 13 to 21 years old who had a diagnosis 
of chronic kidney disease or inflammatory bowel disease for at least three months were 
approached to participate. If an individual (or their caregiver if they were less than 18 years old) 
did not speak English fluently, they were excluded from the study. Also, patients with significant 
cognitive or developmental delays were excluded. This study recruited 110 patients. Medical 
eligibility was determined by consulting with the patient’s physician and/or a chart review. 
Those with CKD stage 3 or higher or a diagnosis of IBD were eligible to participate regardless of 
how long they have received treatment at UNC.  
The patients at the UNC Kidney Center live an average of 75 miles (one way) away from 
the clinic. At the present time, there are approximately 100 patients with CKD stage 1-4; 100 
patients who have received a kidney transplant; and 10 who are currently on dialysis. On average 
the adolescents in this population take approximately 9.1 (SD=5.8) medications per day. There is 
a large prevalence of minorities in the Kidney clinic, which is reflective of the larger population 
of individuals who are diagnosed with CKD. Conversely, patients at the GI Clinic typically live 
close to the hospital as there are more GI doctors across the state. At the present time, there are 
approximately 150 patients with IBD being treated at UNC. On average the adolescents in this 
population take a similarly high number of medications per day as those with CKD. The majority 
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of patients being treated for IBD at UNC are Caucasian which is reflective of the larger 
population of individuals who are diagnosed with IBD.  
Procedure 
After full approval from the institutional review board was obtained, potential 
participants were recruited in one of two ways, either from the UNC outpatient clinic or over the 
phone. Recruitment at the UNC Chapel Hill Pediatric outpatient clinic proceeded as follows. 
Once the potential participant and their caregiver were brought out of the clinic waiting area and 
into a private room, the primary investigator (PI) or a research assistant approached the family. 
They waited until the patient had entered a private room helped to ensure confidentiality and 
privacy. The study was briefly described to the potential participant and their caregiver if they 
were less than 18 years old or to the young adult alone if they were 18 or older. The study was 
described as being conducted to better understand how a person’s thoughts and feelings 
influence their medication taking. Next, it was explained that as a thank you they would receive a 
10$ gift-card for participating and that, hopefully, the results of the study will allow doctors and 
psychologists who work with CKD/IBD patients to better understand their experience. 
Subsequently, the patients were told that approximately 30-45 minutes would be needed for them 
to complete all of the questionnaires. Finally, the primary investigator waited silently in the room 
for a minute to allow the potential participant (and their caregiver if applicable) to decide if they 
would like to participate. 
If a desire to participate was expressed, informed assent and consent was obtained from 
the participants and guardians, as appropriate. The scales as well as the consent forms were 
completed on computers through the web survey tool ‘Qualtrics.’ Every effort was made to 
ensure the confidentiality and privacy of all participants. When logging onto the program, 
30 
 
participants entered their study ID number into the computer. Only the study’s PI had access to 
the master list that paired the participant’s name to their study id number. There are no known 
personal risks or discomforts associated with participating in the study. Once enrolled in the 
study, the participant were administered the scales. The patient completed scales that gather 
information about their perceived susceptibility, severity, benefits, barriers, family support, self-
efficacy, personal control, peer social support, social-desirability, coping strategies, 
demographics, and medication non-adherence. The participant’s pharmacy was also called to 
obtain a record of their medication refill history for the past year. Finally, the participant’s 
physician was approached and asked to rate the patient’s non-adherence and disease severity. 
The second way in which participants were recruited was over the phone. This was 
completed for patients at the UNC Kidney and GI Center who did not have an appointment 
scheduled during the recruitment period. This was fairly common as many patients only have 
one appointment every six months. Adolescents were called, and if they expressed interest in 
participating, they were e-mailed the link to access the Qualtrics website. Additionally, they were 
provided a confidential study ID number and the PI’s study phone number. Participants were 
prompted for the ID upon logging into Qualtrics. The study ID allowed confidentiality to be 
maintained, while at the same time allowing the PI to match the study IDs with participants’ 
names when the chart review was being completed. The PI’s study phone number was provided 
so that if participants had any questions or concerns, they could have these concerns addressed 
prior to beginning the study. For those potential participants who were less than 18 years old, 
Qualtrics prompted the participant to get their caregiver. Their caregiver must have agreed to the 
study consent form and HIPAA form in order for their child to be allowed to participate. Next, 
the patient was prompted to review their own consent and HIPAA form. They had to agree to the 
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study consent form as well as the HIPAA form to be allowed to participate. If they agreed to 
both forms, the study questionnaires appeared.  
As previously mentioned, after study completion, the participant’s pharmacy was called 
to obtain a record of their medication refill history for the past year. Additionally, the 
participant’s physician was approached and asked to rate the patient’s non-adherence and disease 
severity.  
Measures 
 The measures used to assess the factors of the Adolescent Health Belief Model, coping 
strategies, and social desirability are all self-report scales that have been validated in chronic 
illness populations. Also, scales assessing the physician’s report of the participant’s non-
adherence and disease severity will be discussed. Finally, the exact procedure used to obtain and 
calculate the medication possession ratio will be discussed. 
Perceived susceptibility. This scale was created for the current investigation based on 
several previously published scales (Vollrath,  Knoch, & Cassano, 1999; Weinstein, 1984). This 
five question self-report questionnaire asked participants to rate how likely they are to 
experience a number of different negative outcomes when they compare themselves to peers 
with a similar illness. For example one question asked, “Compared to other with a similar illness, 
if I don’t take my medications as prescribed, my chances of developing complications where I 
have to spend multiple days in the hospital are.” Participants responded on a 7-point scale that 
ranged from “much below average” to “much above average.” 
Perceived severity and perceived benefits. The Beliefs About Medication Scale (BMQ;  
Riekert & Drotar, 2002) consists of 17 questions. These questions assessed two domains: 
perceived severity and perceived benefits of the medications. An example of a question that 
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assessed perceived benefits is, “I have a lot to gain from taking my medicine the way the doctor 
says I should.”  An example question from the perceived severity subscale is, “If I do not take 
my medicine the way I should, I will get sicker.” Participants indicated their degree of agreement 
with each statement on a 5-point Likert scale, ranging from 1-5 (strongly disagree to strongly 
agree). The subscales demonstrate good reliability as evidenced by Cronbach’s alphas of .79–.87, 
mean item-total correlations of .44–.53, and 3-week test-retest results of .71–.77. The severity 
questions in this scale all tapped into long term consequences of non-adherence (Riekert & 
Drotar). As the two illness populations have different long term and short term consequences of 
non-adherence, it was important to understand the differential influence that these consequences 
might have in influencing non-adherence. Therefore, four questions examining the perceived 
severity of short-term consequences were added to the questionnaire. For example, one question 
that was added asks, “If I do not take my medicine the way I should, I quickly begin to feel 
poorly.” 
Perceived barriers. The Adolescent Medication Barriers Scale (AMBS; Simons & Blount, 
2007). The AMBS is a self-report measure designed to assess adolescent-perceived barriers to 
medication adherence. An example question is, “I do not want other people to notice me taking 
the medicine.” All items are rated on a 5-point Likert-like scale from, ‘‘strongly disagree’’ to 
‘‘strongly agree.’’ The AMBS consists of 17 items with a maximum score of 85. The sample 
mean for the scale is 38.1 (SD = 10.7). The Cronbach’s alpha of the total scale was .86 indicating 
strong internal consistency. There are three subscales: disease frustration/adolescent issues (α = 
.84), ingestion issues (α = .70), and regimen adaptation/cognitive issues (α = .76; Simons & 
Blount, 2007). An example of a question from the disease frustration/adolescent issues subscale 
is, “I feel that it gets in the way of my activities.” A question from the ingestion issues subscale 
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is, “I don’t like how the medicine tastes.” The subscale assessing regimen adaptation/cognitive 
issues includes question such as, “I am not organized about when and how to take the medicine.” 
Self-efficacy. The Brief Measure of Diabetes Self-Efficacy (Iannotti et al., 2006). This 10 
item short scale was created for participants with Diabetes; therefore, the questions were slightly 
modified to reflect IBD and CKD. Specifically in each question, the words your diabetes was 
replaced with your illness. For example, all questions began with, “How sure are you that you 
can do each of the following, almost all the time?” The original survey next stated, “Identify 
things that could get in the way of managing your diabetes.” In the version used for this study, 
the questions read “Identify things that could get in the way of managing your illness.” 
Participants responded on a 10-point scale ranging from, “not sure at all” to “a lot”. Cronbach’s 
alpha for this scale is high (.90), and the test-retest intraclass correlation coefficient for the 
measure is .89. The mean for the scale is 7.52 (SD =1.58). Additionally, a scree plot indicated 
that all items have a factor loading of at least .53 (Iannotti et al.).  
Family support. The Diabetes Social Support Questionnaire-Family Version (DSSQ-
family; La Grecca & Bearman, 2002) is a self-administered 58 question measure that assesses 
adolescents’ perceptions of their family’s behaviors relative to their disease. The scale included 
questions about both instrumental support and emotional support. Many of the questions in the 
original scale asked about tasks not relevant to the care of CKD or IBD (i.e., asked about the 
results of blood tests); thus, all non-relevant questions were eliminated, and the version used in 
this study included 13 questions.  This shorter version has also been used in prior investigations 
(Hsin, La Greca, Valenzuela, & Delamater, 2010). There is high internal consistency across the 
13 items (α = .91). The concurrent validity of the measure indicates that adolescents who report 
more frequent family support for their illness view their families as more emotionally supportive 
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(r = .47, p < .001), and more cohesive (r = .34, p < .01) than adolescents who report less frequent 
family support (La Grecca & Bearman, 2002).  As the questionnaire was originally designed to 
be used with adolescents who have diabetes, each relevant question replaced the word diabetes 
with your illness. For example, in the question (How often does a family member) understand 
when you sometimes make mistakes in taking care of your diabetes, diabetes was changed to 
your illness.   
When completing the measure, participants were first asked the frequency with which 
each behavior occurs (“How often does a family member……?”) from 0 to 5 (where 0 = never 
and 5 = at least once a day). Next, participants were asked to provide a rating of the perceived 
supportiveness of the behavior (“How does this make you feel?”) from -1 to 3 (-1 = not 
supportive and 3 = very supportive).    
 Personal control. The Perceived Control subscale from the Revised Illness Perception 
Questionnaire (IPQ-R; Moss-Morris et al., 2002) was employed. This six question self-report 
sub-scale asked participants about their level of perceived control over their illness. For example 
one question states, “The course of my illness depends on me.” Responses are on a 5-point 
Likert-like scale from “strongly disagree” to “strongly agree.” Higher scores indicate a higher 
level of perceived control. This sub-scale has good internal reliability (.81) and good test-retest 
reliability (.57; Moss-Morris et al.). 
Peer support. The Diabetes Social Support Questionnaire-Friend Version (DSSQ-Friends; 
Bearman & La Greca, 2002) is a self-administered questionnaire that assesses adolescents’ 
perceived peer support for taking their medications. The scale includes four questions about 
emotional support.  As the questionnaire was originally designed to be used with adolescents 
who have diabetes, each question replaced the word diabetes with your illness. For example, in 
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the question (How often does a friend) let you know they understand how important it is for you 
to take medications for your diabetes, diabetes was changed to illness.   
Similar to the DDSQ-Family, when completing the measure, participants were first asked 
the frequency with which each behavior occurs (“How often does a friend……?”) from 0-5  
(0= never and 5= at least once a day). Next, participants were asked to provide a rating of the 
perceived supportiveness of the behavior (“How does this make you feel?”) from -1- 3 (-1= not 
supportive and 3= very supportive).  The scale has acceptable levels of internal consistency (rs > 
.70), the re-test correlations are high (.78 - .94)  (Bearman & La Greca).  
 Social desirability. The Marlow-Crown Social Desirability Scale, Short-Form (Reynolds, 
1982) is a13 item self-report scale that examines a person’s level of social desirability. For 
example, participants answered true or false to multiple statements such as, “I sometimes feel 
resentful when I don’t get my way.” The item to total score correlations range from .32 - .47, and 
the scale is highly correlated with the Marlow-Crown standard form (.93). The total mean is 5.31 
(SD = 2.90). All items have a factor loading of .4 or above (Ballard, 1992). 
Coping. This scale was created for the current investigation based on the KidCope 
(Spirito, Stark, & Williams, 1988). The adolescent was first asked to think about taking their 
medications. Then, they were asked about the coping strategies used to manage taking their 
medications. Only the coping styles of positive problem solving and denial were included in this 
study. The coping strategies that the children endorse are used to create a frequency score (how 
often did you do this?) and an efficacy score (how much did this help?). Each of these responses 
are given on a 4-point Likert-type scale ranging from, “not at all” to “almost all the time” for the 
frequency question, and “not at all” to “very much”  for the efficacy question.  
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Several studies using a number of different samples, including children with medical 
illnesses, have been conducted to establish the reliability and validity of this measure. Reliability 
scores have ranged from moderate (0.41) to fairly high (0.83; Spirito et al., 1988). Moderate to 
high construct validity was found (.33 - .77; Patterson & McCubbin, 1987; Spirito et al., 1988; 
Tobin, 19991).  
Disease severity. Severity of Illness Scale (Young-Salem & Prevatt, 2001). This six 
question scale asked the doctor to report on a number of different disease characteristics, so that 
an overall disease severity estimate could be obtained. The responses range from 1-7 with 1 
representing lower disease severity and 7 representing higher disease severity. For example, one 
question states, “How many times a year does this child require a hospitalization,” a response of 
1 indicates 0 hospitalizations and a response of 7 indicated multiple hospitalizations. The scale 
has good reliability with a Cronbach’s Alpha of .79; additionally, the mean usefulness rating 
from 1-5 was a 4.97 (Young-Salem & Prevatt). 
Demographic information. This self-report questionnaire was created for the current 
study. It asked patients their demographic information such as age, race, gender, age at 
diagnosis, and insurance status. 
 Non-adherence. The following methods each sought to measure what percent of the time 
participants did not take their medications. This percentage was derived in the following three 
different ways:  
Self-reported non-adherence. The Medication Adherence Measure (MAM; Zelikovsky, 
Schast, Palmer, & Meyers, 2002) was used to assess medication non-adherence. Participants first 
reported the name of each medication that they were prescribed, and if they could not remember 
all their medications, they were reminded of them (obtained by chart review). Next, participants 
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self-reported how many doses of each medication they missed in the previous seven days. The 
number of missed doses, divided by the number of prescribed doses, times 100, yielded the 
percentage of missed doses. The MAM is one of the most frequently used methods to assess self-
reported adherence. Data on the MAM suggest adequate convergent validity with established 
measures of non-adherence. For example, in one study of outcomes among renal transplant 
recipients, the percent of missed doses identified on the MAM was associated with the number of 
documented acute rejection episodes by year 2 post-transplant (r = 0.62, p < 0.001), suggesting 
good predictive validity of clinical outcomes (Schast, Palmer, & Meyers, 2002).  
 Caregiver rated non-adherence. The adolescent’s caregiver was asked to confidentially 
rate what percent of the time they think the participant does not take their medications. 
Physician rated non-adherence. The physician was asked to confidentially rate what 
percent of the time they think the participant does not take their medications. Asking the 
physician one question as an estimate of participant adherence is a common method across 
studies (Cluss & Epstein, 1985; La Greca, 1988a; Mathews & Christophersen, 1988).  
 Medication Possession Ratio (MPR) – objective adherence. The participant’s pharmacy 
refill record for one year prior to the date of study participation was obtained and used to 
calculate the 3 month MPR. Prior studies have found that the MPR for a 3 month period is 
representative of the patient’s typical adherence (Andrade, Kahler, Frech, & Chan, 2006); thus, 
this time period was also used for the current study. The pharmacy refill record includes a list of 
medications and each date that it was (re-)filled at that pharmacy. MPR in this study was defined 
as the proportion of medications obtained by the participant during a specific time period (MPR 
= (number of days the participant did not have a supply of the medication during the observation 
period / number of days in observation period) * 100). For example, if a participant obtained a 30 
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day supply of their medication and filled the first dose on 1/1/12, the second dose on 2/7/12 and 
the third dose on 3/20/12, there would be 19 days where the participant did not have the needed 
medication. It can therefore be inferred that the participant was non-adherent for these 19 days. 
Using the equation mentioned above, 19 is divided by 90 (90 days in 3 months) and then this 
number is multiplied by 100. This person is non-adherent, therefore, 21.1 percent of the time. 
This methodology is consistent with multiple other studies (e.g., Andrade, Kahler, Frech, & 
Chan, 2006). Different studies have included different medications in the MPR analyses. As this 
investigation is examining non-adherence across two illnesses which have very different types of 
prescribed medications, all prescription medications were included.  
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CHAPTER 3: DATA ANALYSIS 
A total of 110 participants completed all portions of the study. Twenty-three participants 
began the study but did not complete the on-line portion at home (23/140=16.43%). Two 
participants completed the study, but it was later determined that they were ineligible. Therefore 
they were not included in any further analyses (2/140=1.43%). Five individuals refused to 
participate in the study (5/140=96.43% participation rate).  
 The sample consisted of 51 males and 59 females. The majority of the sample had private 
insurance (n=61), followed by public insurance (n=42). A few participants did not have any 
insurance (n=4) or had both public and private insurance (n=3). The majority of the sample was 
Caucasian (n=62), followed by African American (n=34), and Hispanic (n=9). The average age 
of the sample was 16.92(±1.93). The majority of the sample reported that they did not have a job 
(n=80), followed by a part-time seasonal job (n=11), and a year round part-time job (n=13).
 The composition of the CKD (n=55) and IBD (n=55) samples were not significantly 
different in terms of gender (F(1, 108) = .91, p =.34), or whether the participant had a job (F(1, 
108) = .20, p =.66). There was a significant difference between the ethnic composition of the two 
samples (F(1, 108) = 15.71, p =.00), such that there were significantly more African Americans 
in the CKD sample than in the IBD sample. Additionally, there were significantly more Hispanic 
individuals in the CKD sample than in the IBD sample. These results reflect the broader 
population of participants with CKD and IBD being treated at the UNC Hospital. There was also 
a significant difference between the type of insurance that the two samples had (F(1, 108) = 
18.06, p =.00), such that the CKD sample had significantly more public insurance and 
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significantly less private insurance. Finally, the average age between the two samples was 
significantly different (F(1, 108) = 4.66, p =.03), such that the CKD sample was older than the 
IBD sample (CKD is .78 of a year older on average). 
 When comparing the disease characteristics of the two samples, results indicated that the 
CKD (µ=6.36, ±3.65) sample was prescribed significantly more medications than the IBD 
sample (µ=3.67, ±2.02; F(1, 108) = 22.91, p <.001). Additionally, the providers’ rating of the 
participants’ disease severity was significantly different F(1, 79) = 3.84, p=.05. On average the 
CKD sample (µ=18.08, ±6.72) was rated as having more disease severity than the IBD sample 
(µ=15.52, ±3.56; Table 1).  
Hypothesis 1. The aim of the originally proposed hypothesis was to characterize the 
associations among the four different measures of non-adherence (caregiver rating, doctor rating, 
adolescent rating, and MPR) and determine which measure(s) of medication non-adherence 
should be used in the subsequent hypotheses. First, descriptive information about each of the 
four different measures of non-adherence is provided below. 
Caregiver non-adherence ratings were obtained on 105 participants. Two caregivers did 
not speak English; one caregiver was unable to be reached despite multiple attempts, and two 
caregivers reported that because their child did not live at home, they felt uncomfortable 
providing an estimate of non-adherence. Overall the caregiver’s estimated that their adolescent is 
non-adherent 13.95% (range 0-100, ±20.08) of the time. This information was primarily 
provided by the adolescent’s mother (n=73), followed by their father (n=25), and other 
caregivers (grandfather (n=1), grandmother (n=2, aunt (n=2), and guardian (n=2)). The 
caregivers reported that most frequently the adolescent is in charge of their medications (n=58), 
followed by their mother (n=39), father (n=4), grandmother (n=2), and aunt (n=2). Results 
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indicated that the average non-adherence rating provided by the caregivers of adolescent’s with 
CKD (µ=1422, ±22.30) were not significantly different from those with IBD (µ=13.70, ±17.94; 
F(1, 103) = .02, p =.90; Table 2).  
The adolescents’ rating of their own non-adherence was obtained by all 110 participants. 
The average rating of non-adherence was 16.91% (range 20-100; ±16.18). Results indicated that 
the average non-adherence rating provided by the adolescents with CKD (18.00% (±14.71)) and 
those with IBD (15.82% (±17.61)) were not significantly different (F(1, 108) = .50, p =.48; Table 
2).  The adolescents reported that most frequently they are in charge of their medications (n=75), 
followed by their mother (n=24), father (n=6), grandfather (n=2), grandmother (n=1), and aunt 
(n=1). This information could not be obtained from one adolescent. 
A doctor’s rating of non-adherence was obtained for 107 of the participants. Three 
participants were only occasionally seen at UNC and, therefore, did not have a provider who 
knew them well enough to provide a non-adherence rating. The average rating of non-adherence 
was 18.46% (range 0-100; ±19.03). Results indicate that the doctors provided similar ratings of 
non-adherence across both the CKD sample (19.53(±21.11)) and the IBD sample 
(17.41(±16.87); F(1, 105) = .33, p =.57; Table 2). 
The MPR was calculated for 99 participants. Six participants had the incorrect pharmacy 
listed in their electronic medical record and, despite multiple attempts, the updated information 
could not be obtained. Two participants obtained their medications from a pharmacy that 
changed ownership and no longer had the prescription refill history. We were unable to obtain 
the record for 3 participants because the pharmacy did not provide the information after multiple 
contacts. All medications were used to calculate an overall MPR. The MPR results indicated 
that, on average, the sample was non-adherent to their medications 44.17%(±30.00) of the time. 
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There was not a significant difference between the MPR obtained for the participants with CKD 
(44.93 (±31.40)) and those with IBD (43.36(±29.73); (F(1,97) = .07, p=.80). 
Hypothesis 1A. Hypothesis 1A stated that non-adherence obtained by MPR would be 
highest (µ=44.17), followed by non-adherence by doctor report (µ=18.46), adolescent self-report 
(µ=16.91), and caregiver report (µ=13.95).  
To examine if the means of the different measures of non-adherence were significantly 
different from each other, a repeated measures ANOVA was conducted. It was found that there 
was a significant difference among the different measures of non-adherence (F(2.26, 207.74)= 
40.61, p=.00; Table 2). Specifically, there was a significant difference between the non-
adherence obtained by MPR and the caregiver (p<.001), adolescent (p<.001), and the doctor 
(p<.001). The repeated measures ANOVA also indicated that the caregiver rating was not 
significantly different from the doctor rating (p=.41) or adolescent rating (p=1.00); nor was the 
doctor rating significantly different from the adolescent rating (p=1.00). This suggests that the 
objective measure of non-adherence (as calculated by MPR) is significantly different from the 
subjective measures of non-adherence (doctor, caregiver, adolescent report). Furthermore, the 
three subjective measures of non-adherence were not significantly different from each other. 
Thus Hypothesis 1A was partially supported. 
Non-adherence using the Medicaid portal. (employed as a accuracy check of the data) 
The Medicaid portal is an on-line system that tracks the refill history for all Medicaid patients in 
the state of North Carolina. The portal includes refill information from all medications billed 
through Medicaid, regardless of what pharmacy the prescriptions were refilled at. There were 
only 22 patients with information in the Medicaid portal; therefore, this information is only being 
used as a way to check the accuracy of the MPR data. Whereas the MPR is being used as the 
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objective measure of non-adherence, MPR data are subject to errors if participants refill their 
medications at multiple different pharmacies or if they changed pharmacies without the 
awareness of UNC hospital. The Medicaid portal on the other hand is statewide, so it is not 
subject to this potential error; however, it is subject to other types of errors. The results indicated 
that the Medicaid non-adherence score was not significantly related to the caregiver’s score (r= 
.23, p= .30), the doctor’s score (r=.25, p=.27), the adolescent’s score (r= .19, p= .41), or the MPR 
(r= .35, p= .12). These findings suggest that the two “objective” measures of non-adherence (the 
MPR score and the Medicaid portal) are different from each other.  
Hypothesis 1B. Hypothesis 1B stated that social desirability would be a significant 
negative predictor of self-reported, caregiver reported, and doctor-reported medication non-
adherence. It also was anticipated that social desirability would not be a significant predictor of 
the MPR calculated non-adherence. These hypotheses were examined by correlating social 
desirability with each of the four different measures of non-adherence. The results of these 
analyses indicated that: 
The average self-reported social desirability score was 20.64(±2.86; range 13-26). When 
comparing the participants with CKD 20.56(±2.70) and participants with IBD 20.71(±3.03), the 
level of social desirability was not significantly different (F(1, 108) =.07, p= .79). Contrary to 
hypothesis 1B, social desirability was not found to be significantly correlated with the 
adolescent’s self-reported non-adherence (r =.14, p =.15), the doctor’s non-adherence rating (r =-
.04, p =.68), or the caregiver’s non-adherence rating (r =.08, p =.45). As anticipated, social 
desirability was not a significant predictor of the MPR calculated non-adherence (r = -.10, p 
=.34). As social desirability was not a significant predictor of any of the measures of non-
adherence, it was not included in any additional analyses.  
44 
 
Hypothesis 1C. Hypothesis 1C stated that all four measures of non-adherence would 
represent the same underlying latent variable. First, the correlations among the four non-
adherence measures were examined. Results indicated that the caregiver’s rating was 
significantly positively correlated with the doctor’s rating (r=.23, p=.02) and adolescent’s rating 
of non-adherence (r=.41, p=.00). The doctor’s rating, however, was not significantly related to 
the adolescent’s rating (r=.16, p=.09). The MPR score was significantly related to the 
adolescent’s (r=.24, p=.02) non-adherence rating.  
Next, M+ software was used to conduct a confirmatory factor analysis (CFA). This 
allowed for a more thorough examination of the relationships among the variables to determine 
whether all non-adherence indicators are statistically reliable representations of the latent 
construct under investigation. CFA affords several advantages over other analytic techniques in 
that it allows the specification of causal relationships between observed variables and latent 
constructs while simultaneously accounting for item-level measurement error (Bryant & 
Yarnold, 1995). Results indicated that the model is an acceptable fit for the data (χ2(108)=2.85, 
p=0.24; Comparative Fit Index =0.966 (CFI: >.90 acceptable, >.95 excellent; Bentler, 1990; 
Bentler & Bonett, 1980); Tucker Lewis Index=0.897 (TLI: >.90 acceptable, >.95 excellent; 
Tucker & Lewis, 1973); Root Mean Square error of Approximation=0.062 (RMSEA: <.08 
acceptable, <.05 excellent; Brown & Cudeck, 1993). A one-factor solution was derived (Figure 
2; Table 3). Although some of the loadings were lower than desired, the overall indices were 
acceptable and, therefore, it seemed justifiable to use the factor scores in all subsequent analyses 
as the primary dependent variable.  
Hypothesis 2. Hypothesis 2 involved three different components: first to examine the 
amount of variance explained by the Child Health Belief Model; next to examine the amount of 
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variance explained by the Adolescent Health Belief Model, and, finally, to determine whether the 
amount of variance accounted for by the two models was significantly different. It was expected 
that the Adolescent Health Belief Model would explain significantly more variance in 
medication non-adherence than the Child Health Belief Model. Additionally, the specific 
components of the model were examined to determine what individual factors were significant 
predictors of non-adherence. It was expected that perceived susceptibility, perceived severity, 
higher perceived benefits, lower perceived barriers, higher family support, higher self-efficacy, 
higher peer support, and higher personal control would predict lower levels of medication non-
adherence when disease type was controlled for. 
Due to a glitch in the Qualtrics system that could not be rectified even after significant 
interaction with Qualtrics staff; the perceived susceptibility data were deleted for 44 people. 
Despite multiple attempts to restore this data and collaboration with the support team from 
Qualtrics, it was determined that the data were permanently deleted and unable to be recovered. 
One common approach to missing data is to omit those cases with missing data and to run the 
analyses on what remains. This approach is usually called listwise deletion, but it is also known 
as complete case analysis.  Whereas this approach does have important advantages, it would 
result in a substantial decrease in the sample size available for the analyses and, therefore, is an 
undesirable method. Another option is to employ a pairwise deletion. The complication with this 
approach is that the parameters of the model will be based on different sets of data, with different 
sample sizes and different standard errors. Neither of these options is optimal; however, it was 
determined that as the primary goal of this project was to examine the CHBM in its entirety, 
perceived susceptibility should remain in the model and that a pairwise deletion approach would 
be the best method to use with the missing data. 
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Hypothesis 2A. Hypothesis 2A stated that perceived susceptibility, perceived severity, 
higher perceived benefits, lower perceived barriers, higher family support, and higher self-
efficacy would predict lower levels of medication non-adherence when disease type was 
controlled for. The model used to test this hypothesis is written below: 
2A) Medication Non-Adherence(old model) = B0A + B1ASusceptability + B2ASeverity + 
B3ABenefits + B4ABarriers + B5AFamily Support + B6A Self-efficacy + B7ADisease Type 
+ Error 
This hypothesis was assessed by regressing perceived susceptibility, perceived severity, 
perceived benefits, perceived barriers, family support, self-efficacy, and disease type on 
medication non-adherence. The results of the regression indicated that the seven predictors 
explained 27.5% of the variance (R2=.28, F(7,102)=7.20, p<.001). Next, each coefficient was 
examined to see if it was significantly related to medication non-adherence while holding the 
other HBM variables and disease type constant. As anticipated, perceived benefits (β= -.18, 
p=.05), perceived barriers (β= .32, p=.001), perceived susceptibility (β= -.08, p=.33), and self-
efficacy (β= -.23, p=.02) were each significant predictors of non-adherence. Perceived severity 
trended towards significance (β= -.15, p=.08). Family support (β = -.03, p= .73) and disease type 
(β= -.05, p= .55) were not significant predictors of non-adherence (Table 4).  
 Hypothesis 2B. Hypothesis 2B stated that personal control and peer support would be 
significant negative predictors of non-adherence when they were added to the model listed in 
Hypothesis 2A. This hypothesis was assessed by adding personal control and peer support to the 
regression analysis discussed above. This more complete model forms the Adolescent Health 
Belief Model, and the resulting prediction was tested through the following equation:  
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2B) Medication Non-Adherence(new model) = B0B + B1B Personal Control + B2B Peer 
Support + B3BSusceptability + B4BSeverity +  B5BBenefits + B6BBarriers + B7BFamily 
Support + B8BSelf-Efficacy + B9BDisease Type + Error 
 The results of the regression indicated that the nine predictors explained 28.5% of the 
variance (R2=.29, F(9,100)=5.60, p<.001). Next, the coefficients for personal control and peer 
support were examined to see if they were significantly related to medication non-adherence 
while holding the other HBM variables and disease type constant. Contrary to hypothesis 2B, 
neither personal control (β= -.01, p=.91), nor peer support (β= .08, p=.42) were significant 
predictors of non-adherence (Table 5). 
Hypothesis 2C. The aim of hypothesis 2C was to determine if the amount of variance 
accounted for when personal control and peer support were included in the model was 
significantly greater than when they were not included in the model. It was hypothesized that the 
Adolescent Health Belief Model (2B) would explain significantly more variance than the Child 
Heath Belief Model (2A). The total variance accounted for by the Child Health Belief Model 
(2A) was R2 = 27.5% , and the total variance accounted for by the Adolescent Health Belief 
Model (2B) was R2 = 28.5%. The AHBM therefore explained 1% more variance than the 
CHBM. In order to determine if the amount of variance accounted for in the AHBM was 
significantly greater than the variance accounted for in the CHBM, the following equation was 
used:  
2C) F = (Regression SSnew.model – Regression SSold.model)/ dfnew.model 
    Residual MSAB 
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The F value (the significance of the difference in R2 between the old and new model) was 
F(1, 109)= .32, p=.81. Contrary to hypothesis 2C, the Adolescent Health Belief Model (2B) did 
not explain significantly more variance than the Child Heath Belief Model (2A). 
After further reflection and review of the items on the family support survey (DSSQ-
Family Version) and the peer support survey (DSSQ-Friend Version), it was determined that the 
peer support and family support surveys included questions about both (a) broader illness 
support as well as (b) medication taking support. As the factors of the CHBM that were 
significant focused on thoughts about medication specifically, it could be that family and peer 
support about medication taking specifically are what is important when understanding non-
adherence. Therefore, additional analyses were conducted using the medication subscale of the 
family support survey (DSSQ-Family Version) and one question from the peer support survey 
that focused on medication taking (DSSQ-Friend Version). The medication subscale consisted of 
eight questions which assessed the family’s emotional and instrumental support around the 
adolescent’s medication taking. The peer support survey consisted of four questions. Three of 
these questions focused on broader illness support, and one of question focused on medication 
taking. These new analyses were completed by regressing perceived severity, perceived benefits, 
perceived barriers, perceived susceptibility, self-efficacy, personal control, disease type, 
medication specific peer support, and medication specific family support onto non-adherence. 
The results of the regression indicated that the nine predictors explained 28.7% of the variance 
(R2=.29, F(9,100)=5.88, p<.001). The overall model continued to be significant. The modified 
variables of medication specific peer support (β= .14, p=.13) and medication specific family 
support (β= .08, p=.43) again were not significant predictors of non-adherence (Table 6). 
49 
 
When examining the frequency with which adolescents engage in these peer support 
behaviors, the rates were very low. For each of the four questions about peer support, the 
majority of participants reported that those behaviors never occur (Table 7). Additionally, when 
examining the frequency with which the adolescents receive family support behaviors, the rates 
were also very low. For each of the eight questions about family support, the majority of 
participants reported that those behaviors never occur (Table 8). 
Hypothesis 3. Hypothesis 3 examined the moderating role of two coping strategies 
(denial and positive problem solving). The first two sub-hypotheses examined the potential 
moderation of the relationship between perceived susceptibility and medication non-adherence. 
It was hypothesized that when participants experience high perceived susceptibility and engage 
in denial, they would have high non-adherence (3A). It was also was hypothesized that when 
participants experience high perceived susceptibility and engage in positive problem solving, 
they would have low non-adherence (3B). Hypothesis 3A was tested using the moderation model 
shown below. 
 
 
 
 
 
The moderation model stated that perceived susceptibility (X1) influences medication 
non-adherence (Y), but the strength of that influence would depend on the value of the moderator 
– coping strategy of denial (X2). The regression equation that was used to test the moderation 
model is written below.  
 = B0 + B1X1 + B2X2 + B3 X1 X2 
(X1) Perceived Susceptibility  (Y) Medication Non-adherence 
 
(X2) Coping Strategy of Denial  
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To determine whether the interaction was statistically significant, the significance level of 
B3 was examined. This example illustrated one specific moderator relationship; however, all 
other moderator relationships were examined in a similar manner. Specifically, for hypothesis 3B 
these steps were again completed with X2 being the coping strategy of positive problem solving.  
Results indicated that neither denial nor positive problem solving moderate the relationship 
between perceived susceptibility and non-adherence (Table 9).  
Hypotheses 3C and 3D examined the potential moderation of the relationship between 
perceived severity and medication non-adherence. It was hypothesized that when participants 
experience high perceived severity and engage in denial, they would have high non-adherence 
(3C). It also was hypothesized that when participants experience high perceived severity and 
engage in positive problem solving, they would have low non-adherence (3D). The regression 
equation that was used to test hypothesis 3A and 3B was again used to examine hypothesis 3C 
and 3D. Specifically, the analyses were completed with X1 being perceived severity and X2 being 
the coping strategy of denial, and again with X1 being perceived severity and X2 being the 
coping strategy of positive problem solving. Results indicated that neither denial nor positive 
problem solving moderate the relationship between perceived severity and non-adherence (Table 
10).  
Hypothesis 4. Hypothesis 4 had three different components. Hypothesis 4A stated that the 
relationship between the perceived severity of short-term consequences and non-adherence 
would be moderated by disease type. For participants with IBD, it was hypothesized that there 
would be a significant relationship between perceived severity of the short-term consequences 
and non-adherence; however, it was hypothesized that this would not be the case for those with 
CKD. This hypothesis was tested using the moderation model shown below.  
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The moderation model stated that perceived severity (X1) would influences medication 
non-adherence (Y), but the strength of that influence depends on the value of the moderator – 
disease type (X2). The regression equation that was used to test the moderation model is written 
below.  
 = B0 + B1X1 + B2X2 + B3 X1 X2 
To determine whether the interaction is statistically significant, the significance level of 
B3 was examined. The findings support hypothesis 4A (R2=.12, F(3,106)=5.97, p<.001), such 
that disease type (B3) moderated the relationship (β=.86, p=.05) between perceived severity and 
non-adherence (Table 11). For participants with IBD, there was a significant relationship 
between perceived severity of the short-term consequences and non-adherence; however, this 
was not the case for those with CKD. 
Hypothesis 4B stated that the relationship between perceived benefits and non-adherence 
would be moderated by disease type. For participants with IBD, it was hypothesized that there 
would be a significant relationship between perceived benefits and non-adherence; however, it 
was hypothesized that this would not be the case for those with CKD. The regression equation 
that was used to test hypothesis 4A also used to examine hypothesis 4B. Specifically, the 
analyses were completed with X1 being perceived benefits and X2 being disease type. To 
determine whether the interaction is statistically significant, the significance level of the 
(X1) Perceived Severity (Y) Medication Non-adherence 
 
(X2) Disease Type  (X1) Disease Type 
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interaction (B3) was examined. The findings support hypothesis 4B (R2=.19, F(3,106)=8.39, 
p<.001), such that disease type (B3) moderated the relationship (β=1.19, p=.02) between 
perceived benefits and non-adherence (Table 11). For participants with IBD, there was a 
significant relationship between perceived benefits and non-adherence; however, this was not the 
case for those with CKD. 
Hypothesis 4C stated that the relationship between personal control and non-adherence 
would be moderated by disease type. For participants with CKD, it was hypothesized that the 
long-term consequences of personal control would be more important when predicting 
medication non-adherence when compared to individuals with IBD. The findings did not support 
hypothesis 4C (R2=.005, F(3,59)=1.10, p=.36). Disease type did not (B3) moderate the 
relationship (β= .67, p=.19) between personal control and non-adherence (Table 12).  
53 
 
  
CHAPTER 4: DISCUSSION 
For individuals with a chronic illness, medication taking has been identified as the key 
component to successful illness management (Finea et al., 2009). When medication is taken in 
accordance with a doctor’s recommendations, it can aid in symptom management and slow 
disease progression. Despite the clear benefits that medications can offer, approximately 55% of 
pediatric populations do not take their medications as prescribed, or are non-adherent (Dunbar-
Jacob & Mortimer-Stephens, 2001; La Greca & Bearman, 2003; Rapoff, 1999). Medication non-
adherence can be measured and defined in a number of different ways; however, studies 
consistently indicate that negative consequences such as graft loss, hospitalizations, and death 
can result (Dew et al., 2001; Falkenstein, Flynn, Kirkpatrick, Casa-Melley, & Dunn, 2004; Kelly 
& Kalichman, 2002; Rohan et al., 2010; Sudan, Shaw, & Langnas, 1997; Van Dyke et al., 2002). 
Non-adherence occurs across all ages, but it is most likely to occur during adolescence. Not only 
is adolescence the age when non-adherence is most likely to occur, it is also the time period 
when physiologically there is an increased risk for disease progression (Gordeuk et al., 2008; 
Seiffge-Krenke, 1998; Sweet et al., 2006). Consequently, many national consensus reports and 
conference proceedings have highlighted the need to better understand factors leading to and 
preventing against non-adherence in adolescence (Finea et al., 2009). Some authors have 
proposed that the best way to understand non-adherence is to have a conceptual model of the 
phenomenon (La Greca, 1990). Despite this call for a conceptual model, adolescents have been 
widely overlooked in the non-adherence literature, and no models to date have been modified or 
created to understand adolescent non-adherence.  
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Thus, the current investigation sought to fill this gap in the literature by first examining 
how to empirically measure non-adherence, evaluating a currently existing non-adherence model 
(the child health belief model), and finally by both proposing and evaluating a developmentally 
appropriate model. First a brief overview of the study’s findings will be reviewed. This will be 
followed by a more through interpretation of the findings, discussion of the study’s limitations, 
and review of potential clinical implications. 
As medication non-adherence can be measured in a number of different ways, the first 
aim of this study was to characterize non-adherence. Results indicated that the four different 
measures of non-adherence map onto the same underlying latent variable, and, thus, a CFA was 
used to calculate individual factor scores. Once the measure of non-adherence was established, 
the CHBM was analyzed. It was determined that the CHBM as a whole was a significant 
predictor of medication non-adherence and that perceived benefits, barriers, and self- efficacy 
were each significant predictors of non-adherence. Perceived severity trended towards 
significance; however, family support and perceived susceptibility were not significant 
predictors of non-adherence. Thus, there is empirical evidence for using the CHBM in 
adolescents. Finally, the AHBM was examined. It was determined that the AHBM as a whole 
was a significant predictor of medication non-adherence, but that it did not account for 
significantly more variance than the CHBM. Additionally, neither of the two factors added to the 
AHBM (peer support and personal control) were significant predictors of non-adherence. Thus 
this study does not provide support for the use of the AHBM over the CHBM.  
As the basis of this study was to gain a more complete understanding of factors that 
predict non-adherence, it was important to first address how to best measure non-adherence. 
There is not an agreed upon method to measure non-adherence in the literature; nor is there a 
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gold-standard approach. Some authors propose that subjective measures of non-adherence (self-
report, caregiver report) are best, whereas other authors highlight the objective nature of methods 
such as medication refill rates and blood levels (Nakonezny et al., 2010). As each of these 
methods have unique strengths and weaknesses, this study incorporated both objective and 
subjective measures of non-adherence and began by examining how these different methods 
were related to each other. Prior research indicated that objective measure of non-adherence 
(MPR) result in higher rates of non-adherence than subjective measures of non-adherence 
(doctor report, self-report, caregiver report; Dimatteo, 2004). It was hypothesized that rates of 
non-adherence would be highest when they were gathered by MPR, followed by doctor report, 
caregiver report, and finally self-report. Results partially supported this hypothesis. The MPR 
data indicated the highest rate of non-adherence, followed by the doctor report, self-report, and 
finally caregiver report. The lowest two ratings of non-adherence were the self-report and 
caregiver report. As prior studies have shown that social desirability influences self-report data, 
it was hypothesized that the adolescents’ non-adherence rating would be influenced by social 
desirability (Arnold & Feldman, 1981; Mortel, 2008). Additionally, given the current order of 
the non-adherence data, it may be that adolescents are providing their caregiver’s more socially 
desirable responses when reporting their medication taking. No studies to date have examined if 
social desirability is a significant predictor of non-adherence; however, many authors have 
proposed that it may be playing an explanatory role in low non-adherence ratings (Malee et al., 
2009).  
The results indicate that whereas a number of adolescents were high on social 
desirability, it was not related to their non-adherence ratings or to their caregiver’s non-
adherence ratings. This result is contrary to the hypothesis. This finding might suggest that 
56 
 
adolescents are not minimizing their non-adherence report to appear more socially desirable; 
their reports might, in fact, reflect their subjective experience. When they think back on the last 
week, they may not remember when they missed their medications; rather, their intention to take 
them may be more pronounced in their memory. As social desirability was not playing a role in 
predicting non-adherence, it was not included in any of the subsequent analyses.  
The descriptive data obtained regarding the different measures of non-adherence provides 
a broader understanding of the relationships among the four measures. As these measures of non-
adherence are each seeking to capture the same underlying latent variable of true non-adherence, 
both objective and subjective measures should map onto the same latent variable.  Despite this 
fact, no studies to date have used a CFA to examine multiple measures of non-adherence at once. 
A CFA affords several advantages over other analytic techniques in that it allows for the 
specification of causal relationships among observed variables and latent constructs, while 
simultaneously accounting for item-level measurement error (Bryant & Yarnold, 1995). It was 
hypothesized that all four factors would load onto the same underlying latent factor. The results 
supported this hypothesis, as the model is an acceptable fit for the data, and a one-factor solution 
was derived. Therefore a methodology that incorporates both subjective and objective measures 
of non-adherence appears to be a valuable approach to employ in future investigations. 
Although some of the loadings are lower than desired, the overall indices were 
acceptable, and, therefore, it seemed justifiable to use the factor scores for further analyses. The 
factor scores derived from the CFA were used in all subsequent analyses as the primary 
dependent variable. This innovative approach allows for multiple different reports of non-
adherence to be taken into account at once and helps to minimize the likelihood of a type I error 
occurring. Once it was determined that the factor scores would be used as the primary measure 
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of non-adherence, the model that incorporates a variety of factors believed to be important in 
non-adherence was examined.  
Many models for understanding health behaviors exist within the health literature. One 
model that has been frequently used to examine health behaviors is the child health belief model 
(Bush & Iannotti, 1990). This model examines how cognitive factors may facilitate or hinder a 
child from engaging in a specific health behavior. This model was originally constructed to 
conceptualize preventative health behaviors, but it has been expanded to understand non-
adherence (Barclay et al., 2007). While the non-adherence literature overall has not been model 
driven, when a model is employed to investigate non-adherence, the CHBM is most frequently 
used. Across a number of studies, results support the use of the individual factors of the CHBM 
in predicting non-adherence. The model as a whole, however, has not been examined in its 
entirety relative to non-adherence. Rather, only one or two specific factors in the model have 
been examined at a time. The current investigation allowed for a more comprehensive 
understanding of medication non-adherence by examining all factors of the CHBM 
simultaneously. This approach allows for the relative contribution of each factor to be examined, 
as well as the significance of the overall model itself to be tested.  
It was hypothesized that perceived susceptibility, perceived severity, higher perceived 
benefits, lower perceived barriers, higher family support, and higher self-efficacy would predict 
lower levels of medication non-adherence when disease type is controlled for. Results indicate 
that this hypothesis was partially supported. The CHBM as a whole was statistically significant, 
and the factors of perceived benefits, perceived barriers, and self-efficacy were each statistically 
significant predictors of non-adherence, above and beyond the other predictors in the model. 
Perceived severity trended towards significance. Conversely, perceived susceptibility and family 
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support were not significant. These findings suggest that perceived benefits, barriers, and self-
efficacy are the key factors when understanding non-adherence. In order to understand these 
findings, a conceptual interpretation of the significant factors will be provided first. This will be 
followed by an explanation of the factors that that were not significant. 
The three significant predictors of non-adherence were adolescents’ perceived benefits, 
perceived barriers, and self-efficacy regarding taking their medications. These factors focused on 
medication specifically, and are both concrete and proximal to the target behavior of not taking a 
medication as prescribed. The significant predictors focus on how the medication tastes, if the 
medications are difficult to swallow, if the medications relieve symptoms, and if the adolescents 
can adhere to their medication regimen even when they are busy. These findings are consistent 
within a broader context of what is known about adolescents generally. Many studies have 
indicated that adolescents are more focused on the present than the future. This may be why 
perceived severity and susceptibility are not significant predictors of non-adherence. Both of 
these factors require the adolescent to think about future implications and predict the likelihood 
of an event.   
Perceived severity trended towards significance when it was put into the model with the 
other factors. There are two alternate explanations for why perceived severity appears to  be less 
important in predicting non-adherence. It may be that perceived severity does, in fact, not play a 
significant role in understanding non-adherence. Prior studies have found that perceived severity 
is a significant predictor of non-adherence (Bond et al., 1992; Brownlee-Duffeck et al., 1987; 
Reed-Knight et al., 2010), but this has been one of the least researched factors in the model. 
Alternatively, the results might be the result of multicollinearity of predictor variables. When 
perceived severity was entered into the regression model by itself, it was a significant predictor 
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of non-adherence. When it was entered into the multiple regression model with all of the factors 
of the CHBM, it was not significant. This pattern suggests that multicollinearity is occurring 
between perceived severity and the other predictor variables. To further understand if 
multicollinearity was occurring, the correlations among perceived severity and perceived 
benefits, perceived barriers, self-efficacy were examined. Each correlation was small to 
moderate; therefore, multicollinearity cannot be ruled out nor can it be identified as the primary 
reason for the lack of predictability of perceived severity.  
The other individual factor that was not a significant predictor of non-adherence is 
perceived susceptibility. Due to an error in the Qualtrics system that could not be rectified even 
after significant interaction with Qualtrics staff, the perceived susceptibility data were deleted for 
44 people. The power analysis that was conducted prior to the start of this investigation 
determined that 105 participants were needed for adequate power. Consequently, it may be that 
there is not enough power to detect a relationship between perceived susceptibility and non-
adherence, even if one in fact exists. Future studies will need to examine further whether 
perceived severity and susceptibility play a unique role in non-adherence, and how to best 
measure these constructs.  
Family support is the final factor that was not a significant predictor of non-adherence. 
This factor differs from the other factors in that it does not focus on the adolescent’s thoughts 
and feelings about the medication, the possible negative consequences if they do not take their 
medications, or their perceived ability to implement the medication regimen. Rather, this domain 
focuses on the adolescent’s perception of other people’s thoughts and behaviors, specifically, 
their family’s support in facilitating medication taking (Bush & Iannotti, 1990). Contrary to what 
was hypothesized, family support was not a significant predictor of non-adherence. Examining 
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the frequency with which these behaviors occurred, it was determined to be a relatively rare 
occurrence. Many adolescents reported that they never or very rarely experience some of these 
support behaviors. In addition to the medication support questions, the family’s broader illness 
support also was examined. These broader family support behaviors did not predict the 
adolescent’s non-adherence, and they also never or very rarely occur. These findings suggest that 
the adolescent’s individual thoughts and beliefs may be more important than their perception of 
the family’s support. Whereas prior investigations found that the family’s support was a 
significant predictor of non-adherence, these studies were conducted in children (Hsin, La Greca, 
Valenzuela, Moine, & Delamater,  2010; Lewin et al., 2006; Reed-Knight, Lewis, & Blount, 
2010; Tucker et al., 2002). Children may require the family’s direct support in a way that is 
different from adolescents.  
There are many clinical implications to the pattern of findings that non-adherence is 
predicted from concrete, here-and-now issues in adolescents’ lives. Interventions targeted to 
address non-adherence should focus on these concrete and proximal behaviors. For example, if 
an adolescent reports a specific barrier to taking their medications, such as not liking the taste of 
the medication, providers should collaborate with the adolescent to solve the barrier. If these 
barriers cannot be solved, it may be beneficial to encourage the adolescent to identify concrete 
benefits to taking their medications. Additionally, when adolescents report many barriers and 
few benefits to their medications, physicians and healthcare providers should know that these 
adolescents may require additional support to maintain their regimen. Examining the factors of 
the CHBM allowed this investigation to determine that perceived benefits, barriers, and self-
efficacy are critical when predicting non-adherence. At the same time, because these data are 
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cross sectional, cause-effect relationships cannot be determined, so the above suggestions must 
be viewed cautiously. 
This is the first study to propose a developmentally appropriate model to conceptualize 
non-adherence in adolescents. Adolescents report being the primary person in charge of their 
medications, and, therefore, the self-control they feel may be important when predicting non-
adherence (Bandura, 1997). Not only do adolescents take more responsibility for their illness and 
medications than children, they spend less time with their family. In fact, as youth move from 
late childhood to early adolescence, their main source of social support shifts to their peers 
(Kerns, Contreras, & Neal-Barnett, 2000). Due to these prior findings, it was hypothesized that 
personal control and peer support would be significant negative predictors of non-adherence 
when they were added to the CHBM. This new more complete model (the adolescent health 
belief model; AHBM) was hypothesized to account for significantly more variance in medication 
non-adherence than the CHBM.  
Results indicate that the AHBM is a significant model for predicting non-adherence; 
however, neither personal control nor peer support were significant predictors of non-adherence. 
Additionally, when the variance explained by the AHBM was compared to the variance 
explained by the CHBM, it was determined that they were not significantly different. This 
suggests that while the model as a whole remained significant, the addition of peer support and 
personal control were not supported by the current study’s results. Peer support may not have 
been significant because, similar to family support, it was a behavior that occurred with 
surprisingly low frequency. In fact, the majority of participants reported that the peer support 
behaviors occur never and less than 10% reported that they occur daily. These findings might 
indicate that among adolescents, the topic of taking medications does not surface in conversation 
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very often. Given that peer support behaviors focused on medication occur so infrequently, they 
might not have a significant effect on non-adherence. It may be that broader peer support is 
important, not support for the adolescent’s illness or medications specifically. Alternatively, it 
may be that peer support is not an important factor when predicting non-adherence. Adolescents 
might believe that taking their medications is important enough that they do not seek out peer 
support for the behavior and take their medications regardless of what their peers think. Whereas 
peer relationships are important at this time of life in general, this does not mean that peer 
support has implications for all domains of functioning among adolescents. Medication might be 
a domain that does not enter into peer interactions, or peers’ responses might not be a salient 
factor in non-adherence. 
Also contrary to what was hypothesized, personal control was not a significant predictor 
of non-adherence. Prior studies have found that when predicting health behaviors, knowing both 
a person’s self-efficacy and a person’s personal control predict significantly more variance than 
knowing either of these factors alone (Bandura, 1997). However, the results from the current 
investigation did not support these prior findings. Personal control may not be a significant factor 
because of multicollinearity among predictors. When personal control was entered into the 
regression model by itself, it was a significant predictor of non-adherence. When it was entered 
into the multiple regression model with all of the factors of the AHBM, it was not significant. 
Additionally, the individual strength of perceived benefits as a predictor decreased when 
personal control was added to the model. These two variables were significantly moderately 
correlated with each other; therefore, it may be that personal control is not adding any new 
information that perceived benefits is not already accounting for. This suggests that personal 
control and perceived benefits are capturing similar variance when explaining non-adherence. 
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Upon additional examination of specific items, it appears that both of these scales posed very 
similar questions. Future research should continue to examine whether personal control plays a 
unique role in understanding non-adherence.  
An additional aim of this study was to examine a possible explanation for previously 
conflicting results across investigations. Prior research has consistently found significant 
associations among perceived severity, susceptibility, and non-adherence; however, the pattern 
of associations among these factors has differed across studies. Some investigations have found a 
positive relationship whereas others have found a negative relationship. These mixed findings 
may be the result of a moderator (i.e., coping style) that leads to seemingly inconsistent findings. 
Exploration of potential moderator effects may provide some insight into the role that perceived 
susceptibility and severity play in predicting non-adherence. More specifically, different 
adolescents have equally high levels of perceived susceptibility and severity, but some 
adolescents engage in one type of coping whereas other adolescents engage in another type of 
coping. These different coping strategies might then result in different levels of non-adherence. 
 It was hypothesized that when adolescents experience high perceived susceptibility or 
severity and engage in positive problem solving, they are more likely to take their medications 
(Tercyak, Goldman, Smith, & Audrain, 2002). On the other hand, when adolescents experience 
high perceived susceptibility or severity and use the coping strategy of denial, they will be less 
likely to take their medications. However, the results did not support these hypotheses. The 
coping strategies of positive problem solving and denial did not moderate the relationship 
between perceived susceptibility and non-adherence, or the relationship between perceived 
severity and non-adherence. These findings may indicate while in theory different coping 
strategies could account for these discrepant findings from earlier investigations, the hypothesis 
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simply is incorrect. Alternatively, it could be that different coping strategies account for these 
different findings, but the measures used did not fully capture positive problem solving and 
denial. Prior investigations have indicated that people most accurately report their coping 
strategies when they think of a specific event. However, the scale used in this study asked 
adolescents how they cope with taking their medications in general; asking about specific 
incidences might have yielded different findings. Additionally, adolescents use a broad range of 
coping strategies (Thompson & Gustafon, 1996). Whereas the current investigation focused on 
individual coping strategies, it might be more productive in future studies to examine coping 
strategies such as wishful thinking, emotional regulation, and cognitive restructuring both 
individually and in combination. 
Across the two chronic illnesses being examined in this investigation, there are multiple 
differences in both the short-term and long-term consequences of non-adherence. Based on how 
adolescents might experience these two disorders differently, a secondary hypothesis examined 
whether specific components of the AHBM model were differentially important in predicting 
non-adherence across the two illness groups. Because individuals with IBD experience strong 
negative, immediate consequences when non-adherent, the perceived severity of these short-term 
consequences and the perceived benefits of the medication may be particularity important factors 
in predicting non-adherence for this group. It was hypothesized that the relationship between the 
perceived severity of the short-term consequences and non-adherence would be moderated by 
disease type. For participants with IBD, it was proposed that there would be a strong relationship 
between the perceived severity of short-term consequences and non-adherence; however, this 
was not thought to be the case for those with CKD. Results supported this hypothesis. 
Additionally, it was hypothesized that the relationship between the perceived benefits of the 
65 
 
short-term consequences and non-adherence would be moderated by disease type. More 
specifically, for participants with IBD, it was predicted that there would be a strong relationship 
between the perceived benefits of short-term consequences and non-adherence; however, this 
would not be the case for those with CKD. Results also supported this hypothesis. These results 
indicate that for adolescents with IBD, the perceived benefits and the severity of short-term 
consequences are especially important. When patients with IBD do not take their medications, 
they have multiple, direct, adverse physiological reactions that remind them to take their 
medications. If adolescents perceive these consequences to be severe and their medications to 
help, they may have lower rates of non-adherence. These findings indicate that some disease 
specific factors should be taken into account when trying to understand whether adolescents will 
adhere to medication plans. However, other factors may not be differentially important across 
diseases. While it was hypothesized that for participants with CKD, the long-term consequences 
of personal control would be more important when compared to individuals with IBD, these 
findings were not supported. This may suggest that personal control does not operate 
differentially across these two illnesses. 
Whereas the above findings provide increased understand of medication non-adherence 
among adolescents with different chronic diseases, there also are limitations in the current study 
that merit discussion.  First, this investigation is a cross-sectional examination of the factors in 
the CHBM and the AHBM that relate to non-adherence. Whereas the hypotheses are predicated 
upon a causal process in which the factors of the CHBM or the AHBM influence the 
adolescent’s medication non-adherence, the cross sectional nature of the current investigation 
precludes such conclusions. The directionality of the hypotheses is logical given past research 
and the current study model; however, it could be that the non-adherence of the adolescent 
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influences their thoughts and beliefs about their medications. Likewise some unexplored third 
variable could explain the above associations. Thus, future longitudinal studies will provide 
opportunities to examine the direction of association, which is important given possible bi-
directionality.  
A second limitation of the current investigation is that recruitment occurred from one 
hospital in one location. This suggests that the results of the study may not be generalizable to 
the remainder of the country. However, the catchment area for the hospital is quite large given its 
role in the treatment of adolescents in NC. Patients’ families often drive from long distances to 
reach the hospital, and the sample includes a range of economic statuses, races, ages, as well as 
two illness populations. In addition, the results should not be generalized to adolescents with 
other chronic illnesses or multiple co-morbid chronic illnesses as both the current findings and 
previous studies suggest that non-adherence may operate differently in different illness 
populations (Lewis & Klieweser, 1996; Miller et al., 2009). Future studies should include multi-
site investigations, along with adolescents with other chronic illnesses or multiple co-morbid 
chronic illnesses. Such investigations would allow for exploring factors within the CHBM and 
the AHBM that are common across diseases as well as factors unique to each disease.  
In addition to these limitations, the current investigation also incorporates a number of 
unique and innovative components. This study is the most comprehensive examination of non-
adherence conducted to date. It took into account both caregiver-report, provider-report, 
adolescent-report, and MPR while also conducting a CFA to examine if these factors represent 
the same underlying latent variable. No previous investigations to date have examined non-
adherence using a CFA data analysis strategy. Also, the non-adherence literature generally has 
not relied upon theoretical models to predict non-adherence. This is the first study to examine the 
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entire CHBM at once when predicting non-adherence. As a result, the relative contribution of 
each factor in the model could be examined as well as the model as a whole could be evaluated. 
The current study also is the first to propose a developmentally appropriate model to 
conceptualize non-adherence among adolescents. As adolescence is a unique developmental 
period, this study incorporated these developmental factors and examined the model in two 
different illness populations. Finally, this is one of the first studies to examine whether the 
different short-term and long term consequences of non-adherence resulted in the factors of the 
CHBM being differentially important for two diseases. The clinical implications of this study are 
important to note as many factors associated with a chronic illness cannot be changed, but the 
cognitive factors of the CHBM can be modified to produce better adherence.   
Concrete, proximal, cognitive factors may be central when trying to understand an 
adolescent’s non-adherence. This is critical for healthcare providers to know as many physicians 
emphasize the long term negative consequences that can result if an adolescent does not take 
his/her medication or future potential side-effects. However, the current results indicate that 
these factors may not be of central importance to the adolescent when considering taking their 
medication. Instead, the provider should emphasize the current benefits of taking the medication 
and help the adolescent to problem solve to minimize barriers.   
In a field that is rarely theoretically driven, this study provides empirical evidence for the 
value of using models when designing and implementing studies examining non-adherence. The 
cognitive factors in the CHBM are relevant across different disease populations, and the various 
components of the model are differentially important given the specific symptoms of the illness. 
For illnesses with immediate consequences of non-adherence short term factors such as short-
term severity and benefits are especially important. This innovative study has important 
68 
 
implications for how to best measure, conceptualize, and provide interventions for medication 
non-adherence among adolescents.   
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Table 1 
Descriptive Data on the Total Sample, the Chronic Kidney Disease (CKD) Sample and the 
Inflammatory Bowel Disease (IBD) Sample 
 
Demographic 
characteristic 
Total 
Sample 
(n=110) 
 
CKD 
(n=55) 
 
IBD 
(n=55) 
ANOVA results –  
comparing CKD sample to  
IBD sample 
Race  
        White 
        AFAM 
        Hispanic 
        Native American 
        Asian 
 
62 
34 
9 
4 
1 
 
18 
26 
9 
1 
1 
 
44 
8 
0 
3 
0 
F(1, 108) = 15.71, p <.001 
 
 
 
 
 
Gender 
        Male 
        Female 
 
51 
59 
 
28 
27 
 
23 
32 
F(1, 108) = .91, p =.34 
Age  
        Mean 
        Standard deviation  
 
16.92 
(±1.93) 
 
17.31 
(±2.05) 
 
16.53 
(±1.74) 
F(1, 108) = 4.66, p =.03 
Insurance 
        Private 
        Public 
        Self-pay 
        Public & Private 
 
61 
42 
4 
3 
 
19 
30 
4 
2 
 
42 
12 
0 
1 
F(1, 108) = 18.06, p <.001 
Do you have a job? 
        Yes, full time 
        Yes, part-time 
        Yes, part-time seasonal 
        No  
 
5 
13 
11 
81 
 
5 
4 
4 
42 
 
0 
9 
7 
39 
F(1, 108) = .20, p =.66 
Number of medications 
        Mean 
        Standard deviation 
 
5.02 
(±3.23) 
 
6.36 
(±3.65) 
 
3.67 
(±2.02) 
F(1, 108) = 22.91, p <.001 
Provider rating disease severity 
        Mean 
        Standard deviation 
 
17.10 
(±5.83) 
 
18.08 
(±6.72) 
 
15.52 
(±3.56) 
F(1, 79) = 3.84, p=.05 
Stage of CKD 
Stage 5 
     Dialysis 
     Transplant 
     Transplant & Dialysis 
Stage 4 
Stage 3 
Stage 2 
 
- 
- 
- 
- 
- 
- 
- 
 
25 
5 
20 
1 
8 
10 
12 
 
- 
- 
- 
- 
- 
- 
- 
-- 
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Table 2 
 
Percent Non-Adherence  
 
Type of 
non-adherence 
measured 
Total 
Sample 
 
CKD  
 
IBD  
ANOVA results –  
comparing CKD sample 
to IBD sample 
Caregiver’s % non- adherence: 
          Mean 
          Standard deviation 
 
13.95 
(±20.08) 
 
14.22 
(±22.30) 
 
13.70 
(±17.94) 
F(1, 103) = .02,  p =.90 
Adolescent’s % non- adherence: 
          Mean 
          Standard Deviation 
 
16.91 
(±16.18) 
 
18.00 
(±14.71) 
 
15.82 
(±17.61) 
F(1, 108) = .50, p =.48 
Doctor’s % non-adherence: 
          Mean 
          Standard Deviation  
 
18.46 
(±19.03) 
 
19.53 
(±21.11) 
 
17.41 
(±16.87) 
F(1, 105) = .33,   p =.57 
Non-adherence % calculated by 
MPR: 
Mean 
Standard Deviation 
 
 
44.17 
(±30.00) 
 
 
44.93 
(±31.40) 
 
 
43.36 
(±29.73) 
 F(1, 97) = .07, p=.80 
Non-adherence % calculated by 
Medicaid portal: 
          Mean 
          Standard Deviation 
 
 
22.36 
(±22.44) 
 
 
22.86 
(±23.72) 
 
 
21.87 
(±20.64) 
F(1, 20) = .124, p= .93 
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Table 3  
 
Confirmatory Factor Analysis (CFA) Model Results 
 
 
 Standardized Model Results     Unstandardized Model Results 
Factor Estimate (S.E.) p value     Estimate (S.E.)   p value 
MPR .27(±.12)   .018     8.24(±3.63)     .023 
Adolescent .81(±.25)   .001     13.29(±4.26)     .002 
Doctor .22(±.15)   .143     4.13(±2.86)     .149 
Caregiver .53(±.18)   .002     10.67(±3.71)     .004 
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Table 4 
  
Analysis of Hypothesis 2A - The Child Health Belief Model 
 
Variable 
 
B SE β 
Perceived benefits -.023 .012          -.182** 
 
Perceived barriers  .024 .007           .316*** 
 
Perceived susceptibility -.019 .019       .082 
 
Perceived severity -.025 .014         -.152* 
 
Self-efficacy -.011 .005          -.232** 
 
Family support -.001 .003       -.031 
 
Disease type  -.086 .144       -.051 
 
*p≤ .10, **p ≤ .05, ***p ≤ .001. 
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Table 5  
 
Analysis of Hypothesis 2B - The Adolescent Health Belief Model 
 
Variable 
 
B SE β 
Perceived benefits -.024 .013  -.186* 
 
Perceived barriers .024 .007     .317*** 
 
Perceived susceptibility .016 .019 .071 
 
Perceived severity -.026 .014  -.158* 
 
Self-efficacy -.012 .005 -.244** 
 
Family support -.002 .003 -.055 
 
Disease type -.065 .149 -.039 
 
Peer support .022 .028 .075 
 
Personal control -.002 .021 -.011 
 
*p≤ .10, **p ≤ .05, ***p ≤ .001. 
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Table 6  
 
Analysis of Model Including Medication Specific Peer and Family Support 
 
Variable 
 
B SE β 
Perceived benefits -.022 .013  -.174* 
 
Perceived barriers .024 .007     .321*** 
 
Perceived susceptibility .014 .019 .062 
 
Perceived severity -.027 .014  -.164** 
 
Self-efficacy -.013 .005 -.261** 
 
Family support 
medication specific 
-.003 .003 -.076 
Disease type -.045 .148 -.027 
 
Peer support medication 
specific 
.035 .022 .140 
Personal control -.001 .021 -.006 
 
*p≤ .10, **p ≤ .05, ***p ≤ .001. 
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Table 7 
  
Frequency of Peer Support Behaviors 
 
Question: 
 
 
The number of people who selected each response  
(total n=110) 
---- Never 
 
< 2 
times a 
month 
2 
times 
a 
month 
Once 
a 
week 
Several 
times a 
week 
Once 
a day 
How often does a friend listen to 
concerns or worries about your illness? 
33 17 11 17 21 11 
How often does a friend encourage you 
to do a good job taking care of your 
illness? 
40 11 14 16 18 11 
How often does a friend understand 
when you sometimes make mistakes in 
taking care of your illness? 
50 16 7 8 19 10 
How often does a friend understand how 
important it is for you to take your 
medications? 
41 7 16 19 17 10 
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Table 8 
  
Frequency of Family Support Behaviors 
 
Question: 
 
 
The number of people who selected each response  
(total n=110) 
---- Never 
 
< 2 
times a 
month 
2 
times 
a 
month 
Once 
a 
week 
Several 
times a 
week 
Once 
a day 
How often does a family member let you 
know they appreciate how difficult it is 
to take medications?5 
30 16 12 18 18 16 
How often does a family member praise 
you for taking your medications 
correctly or on time? 6 
40 8 11 13 21 17 
How often does a family member give 
you your medications?7 
71 7 3 12 10 7 
How often does a family member remind 
you to take your medications?8 
30 12 10 22 22 14 
How often does a family member help 
out when you take your medications?9 
59 7 8 12 12 12 
How often does a family member wake 
up so that you can take your morning 
medications on time? 10 
73 6 4 6 10 11 
How often does a family member change 
their own schedule to get an early start 
too, when you have to take morning 
medications?11 
76 7 2 5 10 10 
How often does a family member check 
after you’ve taken our medications to 
make sure you have done it?12 
40 12 4 15 15 24 
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Table 9 
 
Hypothesis 3A and 3B - Regression Results Examining if Denial or Positive Problem Solving 
were Moderating the Relationship Between Perceived Susceptibility and Non-Adherence 
 
Variable   B SE Β 
 
Perceived susceptibility -.024 .026  -.106 
 
Denial  .022 .123   .043 
 
Perceived susceptibility by denial -.002 .009  -.044 
 
Dependent variable: medication non-adherence 
*p≤ .10, **p ≤ .05, ***p ≤ .001. 
 
 
 
 
Variable 
 
  B SE β 
Perceived susceptibility -.042 .028 -.185 
 
Positive problem solving -.068 .060 -.199 
 
Perceived susceptibility by positive 
problem solving 
.005 .006  .137 
Dependent variable: medication non-adherence 
*p≤ .10, **p ≤ .05, ***p ≤ .001. 
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Table 10 
 
Hypothesis 3C and 3D - Regression Results Examining if Denial or Positive Problem Solving 
were Moderating the Relationship Between Perceived Severity and Non-Adherence 
  
Variable   B SE β 
Perceived severity .001 .018 .005 
 
Denial .073 .157 .139 
 
Perceived severity by denial -.004 .007 -.151 
 
Dependent variable: medication non-adherence 
*p≤ .10, **p ≤ .05, ***p ≤ .001. 
 
 
 
 
 
Variable 
 
  B SE β 
Perceived severity -.016 .018 -.101 
 
Positive problem solving -.187 .124 -.543 
 
Perceived severity by positive 
problem solving 
.009 .007 .483 
Dependent variable: medication non-adherence 
*p≤ .10, **p ≤ .05, ***p ≤ .001. 
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Table 11 
 
Hypothesis 4A and 4B- Regression Results Examining if Disease Type was Moderating the  
 
Relationship Between Perceived Severity or Perceived Benefits and Non-Adherence.  
 
Variable   B SE β 
Perceived severity   .026 .038 .188 
 
Disease type  1.001 .606 .598 
 
Perceived severity by disease type -.049 .025    -.860** 
 
Dependent variable: medication non-adherence 
*p≤ .10, **p ≤ .05, ***p ≤ .001. 
 
  
Variable   B SE β 
Perceived benefits   .025 .034   .199 
 
Disease type 1.602 .779       .957** 
 
Perceived benefits by disease type  -.053 .023     1.190** 
 
Dependent variable: medication non-adherence 
*p≤ .10, **p ≤ .05, ***p ≤ .001. 
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Table 12 
 
Hypothesis 4C- Regression Results Examining if Disease Type was Moderating the Relationship  
 
Between Personal Control and Non-Adherence.  
 
Variable B SE β 
Personal control .064 .072 .368 
 
Disease type .582 .536 .342 
 
Personal control by disease type .059 .044 .671 
 
Dependent variable: medication non-adherence 
*p≤ .10, **p ≤ .05, ***p ≤ .001. 
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Figure 1 
Depiction of the Four Non-Adherence Variables Loading onto the One Latent Construct  
Error Error Error 
Y1 
 
Self-reported 
Non-adherence 
Y2 
 
Doctor-reported 
Non-adherence 
 
Y4 
 
Pharmacy-
reported (MPR) 
Non-adherence  
 
 
True Non-
Adherence 
ξ1 
Y3 
 
Caregiver-
reported  
Non-adherence 
 
Error 
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Figure 2 
Depiction of the Four Non-Adherence Variables with the Standardized Factor Loadings  
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